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ABSTRACT 
Tumors are known to have unique chemical properties, such as low pH (acidosis), high K+ 
(hyperkalemia), and low O2 (hypoxia). Tumor acidosis has been known to influence therapeutic 
activities of chemotherapeutic drugs. Another conventional cancer treatment, radiation therapy, is 
highly dependent on local oxygen concentrations. Hyperkalemia has been recently reported to 
suppress the immune response of activated T-cells. It is also believed that the spatial distribution 
of these analytes and its heterogeneity, are of relevance. Despite the importance of such chemical 
information on tumors, there are no clinically available tools for “quantitative” pH, K+, or tissue 
O2 imaging. Here, photoacoustic (PA) imaging is employed to provide chemical imaging of all 
these target analytes for cancer (pH, O2 and K+). As for pH, we report on an in vivo pH mapping 
nanotechnology. This subsurface chemical imaging is based on tumor-targeted, pH sensing 
nanoprobes and multi-wavelength photoacoustic imaging (PAI). The nanotechnology consists of 
an optical pH indicator, SNARF-5F, 5-(and-6)-Carboxylic Acid, encapsulated into polyacrylamide 
nanoparticles with surface modification for tumor targeting. Facilitated by multi-wavelength PAI 
plus a spectral unmixing technique, the accuracy of pH measurement inside the biological 
environment is not susceptible to the background optical absorption of biomolecules, i.e., 
hemoglobins. As a result, both the pH levels and the hemodynamic properties across the entire 
tumor can be quantitatively evaluated with high sensitivity and high spatial resolution in in vivo 
cancer models. For K+, we extend this technique to ion-selective photoacoustic optodes (ISPAOs) 
that serve at the same time as fluorescence-based ISOs, and apply it specifically to potassium (K+). 
xxi 
 
However, unfortunately, sensors capable of providing potassium images in vivo are still a future 
proposition. Here, we prepared an ion-selective potassium nanosensor (NS) aimed at in vivo 
photoacoustic (PA) chemical imaging of the extracellular environment, while being also capable 
of fluorescence based intracellular ion-selective imaging. This potassium nanosensor (K+ NS) 
modulates its optical properties (absorbance and fluorescence) according to the potassium 
concentration. The K+ NS is capable of measuring potassium, in the range of 1 mM to 100 mM, 
with high sensitivity and selectivity, by ISPAO based measurements. Also, a near infrared dye 
surface modified K+ NS allows fluorescence-based potassium sensing in the range of 20 mM to 1 
M. The K+ NS serves thus as both PA and fluorescence based nanosensor, with response across the 
biologically relevant K+ concentrations, from the extracellular 5 mM typical values (through PA 
imaging) to the intracellular 150 mM typical values (through fluorescence imaging). Lastly, nano-
enabled tissue O2 monitoring by PA, called lifetime-based PA (PALT) imaging, was introduced 
and demonstrated. A known PALT oxygen indicator, Oxyphor G2, is conjugated into 
polyacrylamide nanoparticles, called G2-PAA NP. The oxygen sensing capability of the G2-PAA 
NP has been confirmed in vitro and in vivo studies. In an Appendix, we show how to monitor 
photodynamic therapy (PDT) using the PALT approach to measure the local oxygen depletion as 
a function of PDT time. Oxygen depletion during PDT is monitored using both oximeter and PALT 
spectroscopy in vitro. The latter is enabled by theranostic NPs of methylene blue (MB) conjugated 
PAA, used for both PALT and PDT. This synergistic approach has good potential for personalized 
medicine.  
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Chapter 1: Introduction 
Today, cancer still remains one of the most fatal diseases. Among recent advances in cancer 
treatments, nanotechnology has received much attention due to its uniquely appealing features for 
drug delivery, diagnostics, and imaging. Nanoparticles, containing active molecules such as 
therapeutic drugs, biomacromolecular drugs, imaging contrast agents, etc., have been developed 
specifically for cancer treatments. Several nanoparticles are already FDA approved for cancer 
treatments and many are under clinical trials.1-4 Here, novel methods for imaging tumor chemical 
footprints, specifically pH, tissue O2, and K+, are introduced. 
 
1.1 Advantages of Nanotechnology in Cancer medicine 
Cancer is formed as a result of uncontrollable cellular regeneration. Cancer cells strive for 
more oxygen and nutrients from blood as they require excessive energy for continuous cellular 
regeneration. Tumors, therefore, induce new blood vessel growth (angiogenesis) in order to 
compensate for the lack of nutrients and oxygen supplied for tumor cells that are distant from the 
regular blood vessels. Unlike regular blood vessels, new blood vessels formed by tumors are 
irregularly shaped, with leaky vasculature and lower blood pressure. 
NPs (typically from 10 nm to 100 nm) are too large to penetrate through the regular blood 
vessels, but they are small enough to penetrate through the angiogenic blood vessels. This 
phenomenon grants NPs a passive targeting ability (Enhanced Permeability and Retention effect). 
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Due to the size of the NPs, they are not easily removed from the new blood vessels and accumulate 
around tumors. Besides the passive targeting ability, the surfaces of NPs can be easily engineered 
with one or more specific targeting moieties, such as RGD-peptide, F3-peptide, UM-A9 antibody, 
etc., granting active targeting ability.5-17 
The targeting ability (both passive and active targeting) of NPs is highly attractive for cancer 
medicine. For example, most chemotherapeutic drugs are essentially toxins that kill tumor cells. 
Those drugs are usually not only toxins to the tumor cells, but also to other healthy cells, thus 
causing serious side effects. When the drugs, by themselves, are injected into the bloodstream, 
those drugs circulate and spread all throughout the body without recognizing specific targets. Due 
to this reason, the dosage of the drugs is strictly regulated (i.e. high dosage can cause serious side 
effects while low dosage can lead to none or less therapeutic efficacy). The targeting ability of NPs 
can offer a solution for this dilemma, so as to maximize therapeutic efficacy while minimizing side 
effects. 
The surfaces of the NPs are typically covered by polyethylene glycol (PEGylated). PEGylation 
allows for minimal immune system (such as macrophages) recognition, and thereby, increasing 
retention time and biocompatibility in the bloodstream.18 The NP matrix also serves as a protection 
device for the therapeutic cargoes and/or imaging agents. For example, in the case of pH sensing 
nanoparticles, the NP matrix protects the indicator dye from interacting with bio-macromolecules, 
such as albumin. When the free sensing indicator is allowed to interact with human serum albumin, 
which is the most abundant protein in mammals, the indicator’s optical properties, along with that 
of the pH calibration, changed from their characteristics in an albumin free solution. On the other 
hand, the nanosensor exhibits no difference, whether in the presence or absence of albumins.7 
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1.2 Chemical footprints of cancer 
Besides from their physical characteristics, tumors also exhibit unique chemical characteristics, 
such as low pH (acidosis), low O2 (hypoxia), and high K+ (hyperkalemia). Acidosis and hypoxia 
are explained by the Warburg Effect.19 Tumor cells near the blood vessels take up most of the 
oxygen for themselves, so as to produce more energy, thus reducing the oxygen and nutrients that 
reach tumor cells far away from the blood vessels. As a result, the core of the tumor (the farthest 
from the blood vessels) is known to exhibit hypoxia. Tumors also transform their major metabolic 
pathway from aerobic glycolysis (consumes oxygen) to anaerobic glycolysis (does not consume 
oxygen). A side product of anaerobic glycolysis, lactic acid, is responsible for the acidic (low pH) 
tumor microenvironment causing acidosis. The chemically altered states are believed to cause 
metastasis, local recurrence and angiogenesis.20-22  
Acquiring chemical information is not only providing valuable information to the study of a 
cancer’s nature, but also can directly be translated into a next generation diagnostics and prognostic 
tool for personalized medicine. Well known are hypoxia’s effects of obviating radiation therapy of 
any kind, from high energy radiation treatments to photodynamic therapy, due to the requirement 
of such therapies for the local presence of O2, so as to create the Reactive Oxygen Species (ROS), 
which kill cells. Furthermore, the influence of local pH in relation to the administration of some 
of the commercial chemotherapeutic drugs has been reported, e.g. daunorubicin, doxorubicin, and 
mitoxantrone show reduced therapeutic efficacy under acidic conditions (acidosis); while some 
other drugs, such as chlorambucil, cyclophosphamide, and 5-fluorourcacil, show higher 
cytotoxicity at lower pH.23 
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More recently, hyperkalemia has been reported to be responsible for immunotherapy 
suppresion.24 Hyperkalemia is believed to be caused from a necrotic core of a tumor. As a tumor 
expands, some of the tumor cells lack space, oxygen, and nutrients to survive, leading to necrosis 
in the core of the tumor, leaving a necrotic core, consisting of necrotic cells and debris surrounded 
by live tumor cells.25 Typically, the intracellular potassium concentration is around 150 mM, while 
the extracellular potassium concentration is around 5 mM. Thus, the necrotic cells and debris cause 
a local elevation of potassium ion concentrations (around 5 to 10 folds higher than typical for the 
extracellular potassium concentration).24 
Although the importance of tumor chemical information has been established, a simple and 
generally applicable clinical tool that gives spatially resolved quantitative chemical information 
throughout the tumor is not yet available. Here, a novel chemical imaging method is introduced. 
By combining nanotechnology and photoacoustic (PA) imaging, the chemical information on a 
cancerous tumor can be revealed. 
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1.3 Chemical imaging of cancer (Photoacoustic chemical imaging) 
 
Figure 1.1 Photoacoustic (PA) imaging schematic. Pulsed laser is used to excite the optical 
contrast agent. Absorption by the laser excitation creates thermal expansion causing 
ultrasound emission. The ultrasonic emission is detected by an ultrasound (US) probe 
and the acquired information can be converted into both US and PA images. 
Photoacoustic (PA) imaging is a hybrid imaging modality combining in a unique way 
traditional optical imaging and ultrasound imaging (Figure 1.1).26 An optical contrast agent 
absorbs pulsed non-ionizing radiation, and converts the excited energy into thermoelastic 
expansion which induces a slight temperature increase and ultrasonic emission. The initial pressure 
rise due to a pulsed optical absorption (p0) can be estimated from 
𝑝0 = Γ𝜇𝑎𝐹,                                 (1) 
where Γ is the Grüneisen parameter of the tissue, 𝜇𝑎 is the absorption coefficient, and 𝐹 is the 
local light fluence. As shown in equation (1), the PA signal generated correlates linearly with the 
absorbance of the optical contrast agent, and thus with the optical absorption spectrum. Because 
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ultrasound travels far better than light in tissues, i.e. with little scattering, its imaging depth is 
mostly limited by the excitation light, thus providing a deeper tissue imaging ability than 
traditional optical imaging. Although label-free PA imaging has been widely explored for both 
structural and functional imaging, well-established optical sensors have also been coupled with PA 
imaging.6-8, 27-29 
 
Figure 1.2 Importance of cross-sectional chemical imaging. The O2 concentration and pH 
are known to be lower at the core while K+ concentration is hypothesized to be higher. 
Colorimetric scale bar for O2 and pH is indicated by a downward arrow (red is lower 
and blue is higher), while for K+ it is indicated by an upward arrow (blue is lower 
and red is higher). 
PA imaging is one of the fastest emerging biomedical imaging tools overcoming the imaging 
depth limit of traditional optical imaging modalities. PA imaging detects ultrasound, which 
penetrates far better than light in tissues, rather than light emanating from the sample. Thus, the 
imaging depth limit is only dependent on the excitation light source thus enabling subsurface (or 
cross-sectional) images of the tumor chemical environment, which cannot be accomplished with 
conventional optical imaging. Cross-sectional images of tumors are highly advantageous for 
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chemical imaging because tumors, as explained in the previous section, have necrotic cores, which 
have different chemical footprint compared to the boundary of the tumors, thus forming gradients 
of chemical content (Figure 1.2). 
 
1.4 Outline of the Dissertation 
This dissertation introduces the development of novel chemical imaging methods (quantitative 
and qualitative) with nanoparticle based sensors enabled PA imaging. Each chapter is intended to 
provide a story of developing PA chemical imaging for independent analytes (pH, K+, and O2). 
Nanoparticle based pH, K+, and O2 sensors have been prepared and tested with PA spectroscopy 
and imaging. 
Chapter 2 presents the first demonstration of quantitative pH imaging in vivo (tumor model) 
through photoacoustic imaging.7 We encapsulated commercially available pH indicator dye, 
SNARF-5F, into surface modified polyacrylamide nanoparticles. The nanoparticle encapsulation 
serves not only as a targeted delivery tool but also to protect the SNARF-5F from interference by 
body proteins or enzymes. Such interference is known to cause changes in the dye’s optical 
properties, thus affecting the pH calibration. Utilizing PA, imaging, we hereby propose a method 
and present the “transaxial” pH images of tumors in vivo. There are a few recently reported works 
on PA pH imaging in vivo; however, they are unable to provide quantitative pH images, because 
of background signal interference due to optical absorption by the tissues. We remove from our 
images the background signal from the most absorbing factor in biological tissues, namely, “blood”, 
which allows us to directly provide quantitative pH images. According to our study on a mouse 
cancer model (see example result in Fig. 1), the average pH of the tumors is 6.71 ± 0.22, while the 
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average pH of normal muscle tissues is 7.46 ± 0.095. These results match with “gold standard” pH 
electrode measurements done in situ. Moreover, we see the details of the non-homogenous 
distribution of the pH throughout the tumor, i.e., significant differences between core and periphery 
acidity.  
Chapter 3 presents the first PA and fluorescence optimized potassium sensor.8, 30 The potassium 
selective nanosensor (K+ NS) shows excellent response from 1 mM to 100 mM with PA imaging, 
and from 20 mM to 1 M with fluorescence imaging. Thus, the K+ NS can serve as both 
extracellular K+ sensor (typical concentration ~5 mM, but for cancer 10 mM to 50 mM) and 
intracellular K+ sensor (typical concentration ~150 mM. but less for cancer cells after therapy). 
The K+ NS can be further modified with an external near-infrared (NIR) absorbing/emitting dye. 
Unlike the absorption characteristics of the K+ NS (two signal peaks at 540 nm and 660 nm), there 
is a single fluorescence peak; thus, a secondary reference fluorescence peak is needed. Because 
the K+ NS contains primary amine groups on the surface, it can be utilized for conjugating a 
targeting moiety and/or an NIR reference dye.  
Chapter 4 introduces PA tissue oxygen imaging, called PA lifetime imaging.27 This method is 
an extension of time-resolved (or transient) absorption spectroscopy.6, 28, 29, 31-38  The sensing 
mechanism is similar to that of phosphorescence quenching based oxygen sensors, but it is 
measured by PA imaging/spectroscopy, i.e. it is based on optical absorption rather than emission. 
Nanoparticles containing a known PA oxygen sensing dye, Oxyphor G2, were synthesized. The 
“proof-of-concept” experiment on the O2 sensing nanoparticle’s oxygen sensing capability was 
performed by generating a calibration curve with photoacoustically measured lifetimes and known 
oxygen concentrations. Also, an initial experiment on a mouse model in vivo has been performed. 
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The PA lifetime imaging method is able to differentiate tissue oxygen levels.  
Lastly, chapter 5 contains a summary of the thesis along with a discussion on current limitations 
and future directions regarding each project. 
The Appendix describes the combining of PA lifetime spectroscopy and photodynamic therapy 
(PDT). This is another application of the PA lifetime imaging for oxygen sensing. PDT is a 
promising therapeutic modality for virtually all types of tumors. A photosensitizer (PS), under light 
excitation, converts oxygen into reactive oxygen species (ROS) that lead to high oxidative stress 
within the cell, so as to cause cell death. Since the mechanism of PDT is similar to PA lifetime 
imaging, these can be combined to provide a direct method of monitoring PDT. Employing nano-
technology, we used methylene blue (MB), which is a well-known photosensitizer and also a 
known PA oxygen sensing dye, preparing MB conjugated PAA nanoparticles. The oxygen 
depletion during PDT was monitored using a gold standard oxygen meter as well as PA lifetime 
spectroscopy, in vitro, as a proof of principle for in vivo applications. 
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Chapter 2: Quantitative Photoacoustic pH Imaging 
This chapter has been adapted from a following publication with minor modifactions: 
Jo, J.1; Lee, C. H.1; Kopelman, R.; Wang, X., “In vivo quantitative imaging of tumor pH by 
nanosonophore assisted multi spectral photoacoustic imaging”, Nature Communications, 2017, 8, 
471. 1Indicates co-first authorship (Featured in UM engineering News Center: 
https://news.engin.umich.edu/2017/09/reading-cancers-chemical-clues/) 
 
2.1 Introduction 
The regulation of pH is central to the processes of homeostatic control in mammalian tissues. 
The pH determines the charge state on proteins and macromolecules. Thus pH change can affect 
various pathologies, such as inflammation, renal disease, ischemia, chronic lung disease, and 
intrauterine disorders1-3. In cases of cancer, the tumors are often found in an altered metabolic 
state, which leads to anomalous extracellular chemical composition, such as acidosis (low pH), 
hypoxia (low oxygen), and/or hyperkalemia (high potassium)4-7. Acidity of the tumor is 
explained by the Warburg Effect, which describes how lack of nutrients and oxygen converts the 
tumors’ metabolic pathway from aerobic glycolysis into anaerobic glycolysis8. A side product of 
anaerobic glycolysis, lactic acid, is responsible for the acidic tumor microenvironment, the 
excess lactic acid production surpasses the buffering capacity of the body fluid which thus 
becomes more acidic8. The chemically altered states are believed to cause metastasis, local 
recurrence and angiogenesis, and are among the causes for failure of cancer treatment9-11. 
Although the importance of pathological acidosis has been established, a simple and generally 
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applicable clinical tool that gives spatially resolved quantitative pH information throughout the 
tumor is not yet available. 
Quantitative in vivo pH imaging methods have been developed mostly for magnetic 
resonance imaging (MRI)12-14, positron emission tomography (PET)15, 16, and optical imaging17-
20. MRI and PET based methods have serious limitations such as high cost and limited access. In 
addition, MRI cannot be utilized on patients with pacemakers or implants, and PET utilizes 
ionizing radiation which has safety concerns. Optical spectroscopy based techniques are highly 
desirable due to many advantages such as low cost, non-invasiveness, and ease of use. Optical 
pH imaging has been developed for many decades, historically starting with litmus paper. In 
recent years, numerous near-infrared fluorescent pH indicators have been developed17-20. Based 
on the measurement of the pH-dependent emission spectrum, fluorescence microscopy has been 
heavily used for pH measurements of cells in vitro or of superficial tissues in vivo. However, as a 
result of the strong optical scattering of biological tissues, traditional optical spectroscopy is not 
able to achieve satisfactory spatial resolution when the target tissue is beyond the sample surface. 
This limited spatial resolution in imaging subsurface tumor also inevitably leads to limited 
accuracy in evaluating the cancer microenvironment, because the functional hallmarks of tumor 
including the acidosis also show strong heterogeneity. 
Combining the merits of light and ultrasound, the emerging non-ionizing and non-invasive 
photoacoustic imaging (PAI) holds the potential to overcome these challenges21-24. In PAI, the 
spatial resolution is not limited by the detection of photons which are highly scattered in most 
soft tissues, but instead by the detection of ultrasound waves which are much less scattered. 
Thus, the spatial resolution of PAI is comparable to that of ultrasound (US) imaging which, 
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especially when working at high frequencies, is superior in delineating the morphology of 
subsurface solid tumors. Our group, followed by others, has performed some preliminary pH 
measurements using PAI20, 25-29. A well-known ratiometric pH indicator SNARF-5F, i.e. 5-(and-
6)-Carboxylic Acid, has been explored for qualitative pH measurement in vivo. The emission 
spectrum of SNARF-5F undergoes a pH-dependent wavelength shift, allowing the ratio of the 
fluorescence intensities at two emission wavelengths to be used for the measurement of pH. 
Similar to the emission spectrum, the absorption spectrum of SNARF-5F is also a function of 
pH. Therefore, following the idea of fluorescent dual-wavelength ratiometric measurement, PA 
absorption dual-wavelength ratiometric measurement of SNARF-5F has been explored, and its 
capability in detecting 0.1 pH change has been demonstrated.29 However, due to the severe 
background optical absorption in biological tissues (mostly from hemoglobin), none of the 
previous studies, including ours, has achieved truly quantitative pH measurement of tumor in 
vivo. When the two forms of hemoglobin also contribute to the PA signals, providing accurate 
spatial pH information is nearly impossible without careful consideration of the background 
optical absorption spectrum.  
In this study, we developed a method for quantitative pH imaging of tumor in vivo using PAI. 
To make the pH sensitive nanosonophores, we encapsulated the commercially available optical 
pH indicator, SNARF-5F, into polyacrylamide nanoparticles, which we call SNARF-PAA NPs. 
The NP matrix protects the indicator dye from interacting with large outside molecules, such as 
albumin, while the surface modification of the NPs makes the pH nano-indicator to be both 
tumor targeting and immune system avoiding, allowing more efficient and targeted delivery of 
the pH sensing cargo via intravenous injection30-33. As demonstrated by our previous studies, our 
hydrogel-based standard design of nanoprobes are biocompatible and bio-eliminable34, 35, 
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benefiting potential translation into clinic. As stated, the nanoparticle matrix not only serves as a 
vehicle for delivery but also prevents SNARF-5F interference with/by body proteins or enzymes. 
Such interference would affect the optical properties of the pH indicators and thus invalidate the 
pH calibration. Furthermore, by imaging a tumor with quadruple (i.e. four) laser wavelengths 
and then performing spectral unmixing, the contributions to the PA signals from the SNARF-
PAA NPs and the two forms of hemoglobin (i.e. oxygenated hemoglobin and deoxygenated 
hemoglobin) can be separated. Thus, this method can provide truly quantitative and spatially 
resolved pH information in the tumor. At the same time, additional functional bits of information 
on tumor hemodynamic properties are also mapped, including the spatially distributed total 
hemoglobin concentration (i.e. blood volume) and the hemoglobin oxygen saturation (i.e. blood 
oxygenation).  
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2.2 Results 
SNARF-5F incorporated polyacrylamide pH-sensing nanoparticles 
 
Figure 2.1 SNARF-5F encapsulated polyacrylamide based nanoparticle (NP) synthesis 
and pH-sensing scheme. (a) Two-step synthesis schematic of SNARF-5F 
encapsulated acrylamide-based NP. The surface of the SNARF-PAA NP is modified 
with polyethylene glycol, for immune system avoidance, and with the tumor-homing 
F3 peptides. The normalized optical absorption spectra at different pH levels indicate 
the SNARF-PAA NP’s capability of pH sensing. The absorption at 565 nm, i.e., the 
isosbestic point, can be used as an internal reference point. The absorption at 600 nm 
can be used as a sensing point, which responds to difference in pH level. (b) PA pH-
sensing scheme. The PA signal increases linearly with the optical absorption of NPs. 
Thus, the PA signal amplitude at 600 nm changes as the environmental pH changes; 
while the PA signal amplitude at 565 nm remains unchanged, acting as an internal 
reference signal. 
As shown in the normalized optical absorption spectra (Figure 2.1a), measured by a UV-VIS 
spectrometer, the spectroscopic absorption of SNARF-PAA NPs varies with the pH level. The 
absorption at 565 nm presents an isosbestic point (i.e. the pH independent point). The isosbestic 
point can serve as the internal standard without need for a secondary reference probe. The ratio 
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between the intensity at another optical wavelength, such as 600 nm, and that of the isosbestic 
point correlates with the pH level. The 600 nm is picked because the optical absorption of 
SNARF-PAA NP at this wavelength has a large dynamic range when pH changes from 6 to 8. 
The selection of this wavelength can lead to better sensitivity in pH measurement.  
 
Optical absorption spectra of free SNARF-5F dye 
 
Figure 2.2 (a) pH-dependent optical absorption spectrum of SNARF-5F solution. (b) pH-
dependent optical absorption spectra of SNARF-5F solution mixed with human 
serum albumin (4mg ml-1). 
The optical absorption spectrum of free SNARF-5F dye as a function of pH level is shown in 
Figure 2.2a. Similar to its emission spectrum which undergoes a pH-dependent wavelength shift, 
the absorption spectrum of SNARF-5F also changes with pH. When human serum albumin was 
added in the SNARF-5F solution, the interaction between SNARF-5F dye and proteins can change 
the optical absorption spectra of the dye, as shown in Figure 2.2b. 
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Characterization of SNARF-PAA NP 
 
Figure 2.3 (a) Photo showing SNARF-5F, SNARF-PAA NP, and blank PAA NP solution 
(2mg ml-1 or equivalent dye concentration in PBS pH 7.4). (b) UV-VIS spectra of 
blank PAA NPs and SNARF-PAA NPs at equal concentration (2 mg ml-1). The green 
rectangle indicates the range of the optical wavelengths (i.e. 565-600 nm) for quad-
wavelength ratiometric PAI of tumor pH. 
The blank PAA NP solutions are optically clear in the visible spectrum, as shown in the 
photograph in Figure 2.3a in comparison with the PAA NPs containing SNARF-5F. As checked 
by the UV-VIS spectrometer, the optical spectrum of blank PAA NP solution is significantly 
weaker than that of SNARF-PAA NPs in the wavelength range of 565-600 nm, as shown in 
Figure 2.3b. This weak spectrum of blank PAA NPs measured by the UV-VIS, instead of 
reflecting their optical absorption, should mostly come from their optical scattering of the lower 
wavelength light. 
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Figure 2.4 SNARF-PAA NP size and toxicity characterizations. (a) Transmission Electron 
Microscopy image of SNARF-PAA NPs. Scale bar, 100 nm (b) Hydrodynamic size 
measurements of SNARF-PAA NPs using Dynamic Light Scattering. (c) In vitro 
cytotoxicity test of free SNARF-5F dye, blank PAA NPs, and SNARF-PAA NPs. The 
relative cell viability was calculated for averages and standard error (n=3). The 
concentration marked was based on SNARF-PAA NP concentration. The 
concentration of SNARF-5F dye is equivalent to that loaded in SNARF-PAA NPs. 
A Philips CM-100 transmission electron microscope (TEM) was used for dried size 
determination by negative staining using uranyl acetate. A Dynamic Light Scattering instrument 
(DLS, Delsa Nano C particle analyzer instrument, Beckman Coulter) was used to determine the 
hydrodynamic particle size and zeta potential. The hydrodynamic size of surface modified 
SNARF-PAA NP was ~60 nm (optimum for passive targeting towards tumor); while the 
dehydrated NP size was ~17 nm (Figures 2.4a and 2.4b). The sizes of naked SNARF-PAA NPs 
did not differ significantly from surface modified SNARF-PAA NPs. Zeta potential (surface 
charge) dropped from 26±2.3 mV to 17±1.2 mV as a result of surface modification. The zeta 
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potential was slightly reduced because of the PEGylated surface. 
To test the cytotoxicity, 9L rat glioma cell line (American Type Culture Collection) was 
cultured in RPMI 1640 medium supplemented with 10% Fetal Bovine Serum (FBS) and 1% 
Antibiotic-antimycotic. Approximately 10,000 cells were seeded on 96 well plates. SNARF-5F, 
blank PAA NPs, and SNARF-PAA NPs were dissolved in the culture medium (20 mg ml-1). The 
concentration of free SNARF-5F solution was equivalent to that loaded in SNARF-PAA NPs. 
Appropriate amounts of SNARF-5F, blank PAA NPs, or SNARF-PAA NPs were added and 
diluted with fresh culture medium to make final concentrations of 0.2 mg ml-1, 1 mg ml-1, and 5 
mg ml-1 in each well. Wells that contained cells without being treated with SNARF-5F or 
SNARF-PAA NPs served as the control. After overnight incubation, the culture medium in each 
well were carefully removed and replaced with 100 μL of colourless RPMI. Then, 20 μL of (3-
(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) (MTT) (5 mg ml-1) was added 
into each well and incubated at 37oC for 4 hours. In order to dissolve insoluble MTT formazan 
product, 100 μL of DMSO was added into each well and placed at room temperature for 2 hours. 
The cell viability was analyzed, by measuring absorbance at 590 nm (reference 620 nm), by an 
Anthos 2010 Microplate Absorbance Reader (Biochrom Ltd.) (n=3). The MTT assay result 
(Figure 2.4c) demonstrates that none of free SNARF-5F, blank PAA NPs, or SNARF-PAA NPs 
exhibits any significant cytotoxicity at the concentrations tested. 
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Figure 2.5 Time-dependent fluorescence measurement (540 nm ex/580 nm em) 
demonstrating the kinetics of SNARF-PAA NPs in sensing the environmental pH 
change.  
Based on our former studies, the response time of our PAA NP based nanosensors can vary, 
depending on the nanoparticle composition and matrix36. To study the kinetic response of our 
SNARF-PAA NPs to the change of environmental pH level, we have conducted a time-
dependent fluorescence measurement taken by Horiba Fluoromax-3. The fluorescence 
measurement of a SNARF-PAA NP solution (540 nm ex/580 nm em) was continuously taken 
(once every second) over a period of 1000 seconds. During the measurement, the solution was 
kept stirred using magnetic stirrer equipped within the fluorometer. To change the pH level in the 
solution, small volumes of 1M HCl or 1M NaOH were added alternatively (setting the solution at 
pH 6, pH 7 or pH 8). As shown in Figure 2.5, the fluorescence measurement as a function of 
time demonstrated fast optical response of the SNARF-PAA NPs to the pH change in the solution 
medium. The fluorescent signal from the SNARF-PAA NPs responded within 1 second after 
adding of either HCl or NaOH, and stabilized in a few seconds. The time needed for signal 
stabilization is due to the limited stirring speed. This result, besides validating the quick kinetics 
of the SNARF-PAA NPs, also confirmed their reversibility in sensing the pH level. 
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Figure 2.6 Photostability of SNARF-PAA NPs. The optical absorption of SNARF-PAA 
NP solution (2mg ml-1 in PBS pH 7.4) was measured at different time points during 
a total period of 60 min when the solution was continuously illuminated with 565 nm 
laser beam with homogeneous light fluence of 10 mJ cm-2. The relative absorption of 
the solution is presented as a function of the cumulative light dose. 
To study the photostability, a SNARF-PAA NP solution (2mg ml-1, in PBS pH 7.4) was 
continuously illuminated with a laser beam at 565-nm wavelength and 10 mJ cm-2 light fluence 
over a total time period of 60 minutes. The optical absorption of the solution at different time 
points (i.e. 15 min, 30 min, and 60 min) was measured by the UV-VIS spectrometer. The relative 
percentage change in optical absorption was used to study the photobleaching. Although it has 
been known that SNARF-5F can be photobleached, the photostability of the SNARF-PAA NPs, 
as demonstrated by Figure 2.6, is satisfactory. At 15 min after illumination (accumulated light 
dose 90 J cm-2), the change in optical absorption is about 2% which further increased to about 
10% at 60 min (accumulated light dose 360 J cm-2). This slow speed of photobleaching is highly 
desirable for potential in vivo applications. Using our current system, quad-wavelength 
ratiometric PAI of a tumor takes less than 1 minute for image acquisition at all the four 
wavelengths. The estimated photobleaching during this time period is less than 0.2%. 
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Figure 2.7 Calibration curves of SNARF-PAA NPs at different temperatures. 
To study the potential change of the optical absorption spectrum of SNARF-PAA NPs with 
temperature, we have generated calibration curves at different temperatures, including 25oC 
(room temperature), 37oC (body temperature), 43oC, and 48oC. Each calibration curve reflects 
the ratio between the absorbance at 600 nm and 565 nm (i.e. A600nm/A565nm) as a function of the 
pH level. As shown in Figure 2.7, there is no obvious difference among the calibration curves at 
different temperatures, demonstrating good temperature stability of SNARF-PAA NPs. 
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Nanosensor vs. Molecular sensor 
 
Figure 2.8 The different interactions of free SNARF-5F and SNARF-PAA NP with human 
serum albumin (HSA). (a) Direct observations of the free SNARF-5F buffered at 
different pH of 6, 7, 7.4 and 8. The differences in color can be seen for solutions with 
and without HSA (4 mg ml−1). (b) Direct observations of SNARF-PAA NPs buffered 
at different pH of 6.0, 7.0, 7.4 and 8.0. No obvious difference in color can be seen 
for solutions with and without HSA (4 mg ml−1). (c) pH calibration curves 
(absorbance at 600 nm divided by absorbance at 565 nm) of free SNARF-5F with 
(blue) and without (red) HSA. Significant changes caused by the interaction of 
SNARF-5F with HSA can be noticed. (d) pH calibration curves of SNARF-PAA NPs 
with (blue) and without (red) HSA. No noticeable changes can be noticed, 
demonstrating the advantages of having the dye encapsulated in the PAA matrix. 
In the dye’s free form without being protected by nanoparticles, the SNARF-5F can interact 
with the large proteins in the bloodstream (such as serum albumin). The direct interaction 
between SNARF-5F and proteins can change the optical properties of the dye and thus affect its 
pH sensing capability, as demonstrated in Figure 2.229. The use of nanoparticles can overcome 
this problem and stabilize the optical properties of the dye in vivo. The PAA matrix, which allows 
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penetration of water and ions but not of protein molecules, essentially protects the dye molecules 
from the environment, preventing them from directly interacting with the proteins. To 
demonstrate this improvement, we modeled the interaction of SNARF-5F and SNARF-PAA NP 
with human serum albumin (HSA). The serum albumin is the most abundant protein found in the 
bloodstream, typically ranging from 3mg ml-1 to 5mg ml-1 37. The HSA (4mg ml-1) was added to 
either SNARF-5F free dye or SNARF-PAA NPs in solutions buffered at pH 6, pH 7, pH 7.4 or 
pH 8. The photographs in Figure 2.8a show the color changes of free SNARF-5F after adding of 
HSA; while no obvious color change can be noticed for SNARF-PAA NPs after adding of HSA, 
as shown by the photographs in Figure 2.8b. The calibration curves (i.e. the optical absorption 
ratios between 600 nm and 565 nm at different pH levels) with and without the appearance of 
HSA were shown in Figure 2.8c and Figure 2.8d, respectively, for free SNARF-5F and 
SNARF-PAA NPs. We can clearly see the change in the calibration curve of the free SNARF-5F 
caused by HSA; while the calibration curve of the SNARF-PAA NPs was unaffected after the 
adding of HSA. This study suggested that, compared to free SNARF-5F, SNARF-PAA NP is a 
better choice for in vivo applications where the appearance of proteins cannot be avoided. 
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Dual-wavelength ratiometric PAI of pH 
 
Figure 2.9 Limitation of dual-wavelength ratiometric photoacoustic imaging of 
pH. (a) Spectroscopic optical absorption of oxygenated hemoglobin (HbO2), 
deoxygenated hemoglobin (Hb) and SNARF-PAA NPs at different pH 
levels. (b) Measured PA signal amplitude ratios between the two wavelengths 
(600 nm/565 nm) as a function of pH (pH 5.8–7.8 with 0.1 pH interval) (n = 3, error 
bars represent standard deviations). By performing a linear fitting of the scattered 
measurements in the range of pH 5.8–7.8, a calibration line was generated. (c) The 
PA ratiometric images (600 nm/565 nm) of phantoms containing SNARF-PAA NPs 
buffered at pH 6.6, 7.0 and 7.4, respectively. The nanoparticle (NP) images are for 
phantoms with NPs and the NP + blood images are for phantoms with NPs containing 
blood (1% w/w). The color scale represents the ratio between the PA intensities at the 
two wavelengths (600 nm/565 nm). (d) Estimated errors (i.e., ΔpH) in dual-
wavelength ratiometric PA pH measurement as a function of the ratio between the PA 
signal amplitudes from total hemoglobin (THb) and SNARF-PAA NPs (i.e., ITHb/INP). 
The three curves are for three different hemoglobin oxygen saturation (sO2) levels 
(50, 75 and 100%). (e) Estimated errors (i.e., ΔpH) in dual-wavelength ratiometric 
PA pH measurement as a function of the blood sO2. The three curves are for three 
different ratios of ITHb/INP (0.1, 0.2 and 0.5). PA imaging processing and analyses 
were performed by Dr. Janggun Jo. 
Figure 2.9a shows the optical absorption spectra of SNARF-PAA NPs at different pH levels. 
The optical absorption spectra of oxygenated hemoglobin (HbO2) and deoxygenated hemoglobin 
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(Hb), the major two types of hemoglobin in blood, are also presented. Assuming that the pH 
sensing dye is the only chromophore in the target tissue, ratiometric PA measurements at two 
laser wavelengths are sufficient for quantifying pH level. Although this assumption has been 
adopted by many previous studies including ours29, it cannot stand in most circumstances when 
the optical absorption from background tissue cannot be ignored. In the visible to nearly infrared 
spectral region, the dominant chromophores in most biological tissues are hemoglobin. When 
hemoglobin also contributes to the PA signal, then ratiometric PAI using two laser wavelengths is 
not sufficient anymore for quantifying pH. 
An experiment on phantoms was performed to demonstrate the challenges of ratiometric PA 
pH imaging based on two wavelengths. Before pH measurement, a calibration line for SNARF-
PAA NP was first generated from pH 5.8 to pH 7.8, as shown in Figure 2.9b. This calibration 
line shows the PA intensity ratios between the two wavelengths (i.e. 600nm/565nm) at different 
pH levels. With this calibration line, any ratiometric PA measurement at the two wavelengths 
leads to a corresponding pH level. Phantoms were made of porcine gels containing SNARF-PAA 
NPs, and were buffered at different pH values (i.e. pH 6.6, pH 7.0, and pH 7.4). Each phantom 
was a long cylinder (1.6-mm diameter), and was imaged along the cross section. In one set of 
phantoms, no blood was added and, therefore, the SNARF-5F dye was the only optical absorber. 
In another set of phantoms, whole blood was mixed in each phantom with a concentration of 1% 
(w/w). Each phantom was imaged at the two laser wavelengths (565 nm and 600 nm). With the 
ratiometric measurements, the pixel-by-pixel pH levels in each phantom were calculated. As we 
can see, for phantoms containing no blood, their pH can be measured well by performing dual-
wavelength ratiometric PAI, as shown in Figure 2.9c. However, for phantoms containing blood 
which also contributed to the PA signals, dual-wavelength ratiometric PAI was not able to 
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quantify their pH levels (Figure 2.9c).  
To understand how much the presence of blood in a target tissue can affect the dual-
wavelength ratiometric PAI of pH, a theoretical simulation was conducted. The optical 
absorption of blood is contributed mainly by the two forms of hemoglobin, i.e. HbO2 and Hb, 
which have different optical absorption spectra38. Therefore, not only the total hemoglobin 
concentration (THb) but also the hemoglobin oxygen saturation (sO2) affects the spectroscopic 
PA signal amplitudes from a biological tissue. In simulation, the true pH level was set as 7.4. We 
estimated the errors in pH measurement (i.e. ΔpH) as functions of THb and hemoglobin sO2. 
Since THb affects the ratiometric PA measurement by producing background PA signals, the 
relative contribution of THb is counted as ITHb/INP (i.e. the ratio between the PA signal 
amplitudes from THb and SNARF-PAA NP). As we can see in Figure 2.9d and Figure 2.9e, not 
only the presence of hemoglobin but also the hemoglobin sO2 can strongly affect the accuracy in 
dual-wavelength ratiometric PAI of pH. The error can be large even when the THb is relatively 
low compared to SNARF-PAA NP. For example, even when ITHb/INP is lower than 0.1, meaning 
that the SNARF-PAA NP is still the major optical absorber, the ΔpH can be larger than 1. This 
result suggests that, without considering the impact of hemoglobin to spectroscopic PA 
measurement, quantifying the pH level in biological tissues in vivo is very difficult. For 
characterizing tumor microenvironment, this is especially challenging, as both the blood content 
and the blood oxygenation in cancer tumors are largely heterogeneous. 
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Quad-wavelength ratiometric PAI of pH 
 
Figure 2.10 Quad-wavelength ratiometric PA pH imaging of phantoms. (a) Measured PA 
signal amplitude ratios between the three wavelengths and the isosbestic point (i.e., 
576 nm/565 nm, 584 nm/565 nm, and 600 nm/565 nm) from pH 5.8–7.7 with 0.1 pH 
interval (n = 3, error bars represent standard deviations). By performing linear fittings 
of the scattered measurements in the range of pH 5.8–7.8, three calibration lines were 
generated. (b) Quantitative pH images of phantoms containing different 
concentrations (2, 10 and 20 mg ml−1) of SNARF-PAA NPs buffered at different pH 
levels (pH 6.6, 7.0 and 7.4). The means and the standard deviations of the pH levels 
in each PA image were calculated. The measurement accuracy was better than 0.1 pH. 
The presence of whole blood (1%, w/w) did not affect the quantification of pH levels. 
PA imaging processing and analyses were performed by Dr. Janggun Jo. 
To overcome the problem faced by dual-wavelength ratiometric PAI, quad-wavelength 
ratiometric PAI was developed, as described in detail in the Method section. By working with 
SNARF-PAA NPs buffered at different pH levels from pH 5.8 to pH 7.8, the PA amplitude ratios 
between the three wavelengths (576 nm, 584 nm, and 600 nm) and the isosbestic point (565 nm) 
were measured, as shown in Figure 2.10a. Each scattered point shows the average and the 
standard deviation of the measurements from three samples. The scattered PA measurements for 
the three wavelengths are linearly fitted, leading to three calibration lines, as marked by I576/I565, 
I584/I565, and I600/I565, respectively. The three calibration lines enable quantitative measurement of 
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the pH levels by performing quad-wavelength PAI. Figure 2.10b shows the imaging results from 
gel phantoms buffered at different pH levels (pH 6.6, pH 7.0, and pH 7.4). Although these 
phantoms were also mixed with whole blood at 1%, the quad-wavelength ratiometric PAI 
approach successfully quantified the pH levels in each phantom. In addition, no obvious 
difference can be seen when comparing the results from the three columns in Figure 2.10b, 
suggesting that the result from the quad-wavelength ratiometric PAI method is independent on 
the concentration of the SNARF-PAA NPs. This is extremely important for applications in vivo, 
as the local concentration of SNARF-PAA NPs in the target tissue is difficult to control, and 
could also be highly heterogeneous.  
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In vivo quad-wavelength ratiometric PAI of tumor 
 
Figure 2.11 Example in vivo quad-wavelength ratiometric PAI of a tumor. Each PA 
functional image in pseudo-color is superimposed on the gray-scale US image. The 
tumor area is marked by the dashed line in each image. (a) Quantitative PA pH 
images at different time points after SNARF-PAA NP injection. Scale bar, 2 
mm. (b) PA images showing the distributions of SNARF-PAA NPs at different time 
points after injection. (c) PA image showing the spatially distributed hemoglobin 
oxygen saturation (sO2) in the tumor area at 75 min after injection. (d) PA image 
showing the spatially distributed total hemoglobin concentration (THb) in the tumor 
area at 75 min after injection. PA imaging processing and analyses were performed 
by Dr. Janggun Jo. 
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Figure 2.12 Statistical analyses of the PAI results from the in vivo mouse model. (a) A 
close-up view of the PA pH image of a tumor shown in Figure 2.11 (75 min). The pH 
in the center area (i.e., the area in the solid line) and the peripheral areas (i.e., the area 
between the solid line and the dash line) are averaged respectively. (b) Analysis of 
the SNARF-PAA NP accumulation in the tumors at different time points after 
systemic injection represented by the ratio between the NP concentrations inside and 
outside the tumor (NPIN/NPOUT). With the measurements from four animals (n = 4), 
the average and the standard error for each time point are presented. (c) Example PA 
pH image of a normal tissue (i.e., thigh), showing relatively higher pH. (d) The 
boxplot showing the pH levels in tumors (n = 4) vs. the pH levels in normal tissues 
(i.e., thigh) (n = 4), as quantified from PA pH images. The measurements from 
individual sample (tumors and thighs) are also presented by scattered points. PA 
imaging processing and analyses were performed by Dr. Janggun Jo. 
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An example of time-dependent functional imaging result of a subcutaneous tumor is shown 
in Figure 2.11. Each PA functional image is super-imposed on the gray-scale US image acquired 
at the same time using the same acquisition system. Naturally co-registered with the PA image, 
the US image works well in delineating the tissue structures including the tumor boundary (as 
marked by the dash line in each image). The PA images in the first line show the spatially 
distributed SNARF-PAA NPs in the imaged B-scan section at different time points after systemic 
administration. The NPs were preferentially accumulated in the tumor area gradually, which, we 
believe, is a combined result of the enhanced permeability and retention (EPR) effect and the 
tumor homing F3 peptides. The totally amount NP in the tumor reached a peak at around 75 
minutes after injection. The second line in Figure 2.11 shows the spatially distributed pH levels 
in the imaged section at different time points after injection. By looking at the pH image at 75 
minutes, we can notice that the pH at the center area of the tumor was a little lower than the pH 
at the peripheral area of the tumor. A close view of this pH image at 75 minutes is shown again in 
Figure 2.12a, where the two red lines (solid and dash) marked the center area and the peripheral 
area of the tumor, respectively. The quantitative measurements demonstrate that the averaged pH 
level in the area within the solid line is 6.72 ± 0.29, while the average pH level in the area 
between the solid line and the dash line is 6.97 ± 0.35.  
By performing quad-wavelength ratiometric PAI, we also quantified the spatially distributed 
hemoglobin oxygen saturation (i.e. blood sO2) and the spatially distributed total hemoglobin 
concentration (i.e. THb) within the marked tumor area, as shown in Figure 2.11c and Figure 
2.11d, respectively. The quantified blood sO2 image at 75 minutes shows that the center of the 
tumor area had lower blood sO2 compared to the peripheral area, matching our expectation for 
tumor hypoxia. The THb image at 75 minutes shows that the center of the tumor also had 
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relatively lower blood content. This example imaging result demonstrates that, by performing 
quad-wavelength ratiometric PAI, important functional parameters describing the tumor 
microenvironment, including acidosis and hypoxia, can be quantitatively mapped at the same 
time. 
With the results from four animals, the targeted delivery of SNARF-PAA NPs to the tumors 
after systemic administration was further evaluated. With a pseudo-color PA image showing the 
distribution of NPs (e.g. the images in Figure 2.11a), the average NP concentration in an area 
can be computed by the number of color pixels divided by the total number of pixels. The 
accumulation of NPs in a tumor can be evaluated by the ratio between the NP concentrations 
inside and outside the tumor (i.e. NPIN/NPOUT). A larger ratio suggests better targeted delivery. 
As the result shown in Figure 2.12b, the largest ratio appears at 75 minutes after injection, 
confirming again that the concentrations of NPs in the tumors reached a peak at this time point. 
After the imaging experiment, animal was euthanized, and the accumulations of SNARF-PAA 
NPs in different organs were studied ex vivo. 
An example PA pH image of a thigh is shown in Figure 2.12c which was acquired using the 
same method for tumor imaging. Compared to the pH images from the tumors, as the example in 
Figure 2.12a, the images from the thighs as normal controls show pH levels that are neutral 
(around pH 7.4). The average pH levels in the tumor areas and in the normal thigh muscles from 
four mice were examined (n=4), as shown by the boxplot in Figure 2.12d. The average pH in the 
thigh muscles was 7.46±0.095 while the average pH in the tumors was 6.71±0.22. A t-test was 
performed with a hypothesis that the pH quantified by the quad-wavelength PA ratiometric 
imaging cannot differentiate the tumors and the normal thigh muscles. A P<0.001 was reached, 
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suggesting that the pH values in the tumors measured by PAI were significantly different from 
those in the controls. The imaging finding was confirmed by the measurements from a micro pH 
electrode (STAR A221, Fisher Scientific, Hampton, NH) as the gold standard. The readings from 
the electrode placed at multiple positions in the tumors were in the range of pH 6.4-7; while the 
readings from the electrode placed at multiple positions in the thigh muscles were in the range of 
pH 7.2-7.5. 
 
SNARF-PAA NP accumulations in organs and tumors 
 
Figure 2.13 Organ accumulations of SNARF-PAA NPs. (a) Fluorescence image (ex 560 
nm/em 630 nm) showing SNARF-PAA NPs accumulated in the major organs and the 
tumor dissected from a mouse. (b) Quantified fluorescence intensities were 
compansted with the intensity of tumor and calculated for averages and standard 
deviations in different tissues (n=3). Tmr: tumor, Kdn: kidney, Spl: spleen, Hrt: heart, 
and Lvr: liver. 
The SNARF-PAA NP’s accumulations in organs were studied on a mouse model. As soon as 
the last sets of images were taken, the mice were sacrificed. Then, the organs and the tumor 
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tissues were isolated and kept in 10% buffered formalin acetate solution for 24 hrs. The tissues 
were dissected into thin slices and the fluorescence images (ex 560 nm/em 630 nm) were taken 
using Leica DMIRB inverted fluorescence microscope. The fluorescence intensities were 
quantified using MATLAB. As shown in Figure 2.13, SNARF-PAA NPs were mostly 
accumulated in the tumors and the livers. The liver accumulation is common for intravenously 
injected nanoparticles that are 50-100 nm in size.  
 
Error in pH quantification due to optical attenuation 
 
Figure 2.14 Error in pH quantification due to the spectroscopic difference in optical 
attenuation in tissue. (a) At different depths (2, 4, 6, and 10 mm), the PA signal 
amplitudes at the four wavelengths for ratiometric PAI are normalized to the 
measurements at depth=0 (when the object was not covered by any tissue). The 
spectroscopic differences in the normalized PA signal amplitudes become larger 
when the image depth increases. (b) The estimated error in pH quantified by 
ratiometric PAI as a function of the imaging depth. This error in pH measurement as 
a result of the wavelength-dependent optical attenuation increases with the imaging 
depth. The dash line shows the result of Gaussian fitting.  
We estimated the potential error in pH quantification due to the optical attenuation at 
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different wavelengths for quad-wavelength PA ratiometric imaging. A line target (a black mental 
wire) was covered by slices of chicken breast tissue with different thicknesses (depths=2 mm, 4 
mm, 6mm, and 10 mm, respectively), and measured at the four wavelengths (i.e. 565 nm, 576 
nm, 584 nm, and 600 nm). The PA signal amplitude at each wavelength was then normalized 
respectively by the signal amplitude acquired from the target without being covered (i.e. 
depth=0), as shown in Figure 2.14a. At 2 mm or 4 mm depth, the difference among the 
normalized PA signal amplitudes at the four wavelengths were small (<1%). At 6 mm depth 
which was the maximum tumor depth for the animal model involved in this study, the 
normalized PA signal amplitudes at 600 nm and 565 nm showed a difference of 4.8% as a result 
of the wavelength-dependent optical attenuation. Without compensating this 4.8% difference, the 
estimated error in pH quantification based on ratiometric PAI is 0.16 pH. When tissue depth was 
further increased to 10 mm, a larger difference of 10% was observed between the normalized PA 
signal amplitudes at 600 nm and 565 nm. Without compensating this 10% difference, the 
estimated error in PA pH imaging is 0.34 pH. Figure 2.14b shows the estimated error in pH 
measurement as a function of the imaging depth. As expected, the error becomes larger when the 
imaging depth increases. This error in pH quantification due to the spectroscopic difference in 
optical attenuation in tissue can potentially be compensated by considering the optical fluence in 
the simulation for quad-wavelength ratiometric PAI. 
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Sensitivity of PAI of SNARF-PAA NPs 
 
Figure 2.15 PA signals of SNARF-PAA NP solutions embedded 6-mm deep in optically 
scattering tissue. The signals correspondent to different NP concentrations (0.2 mg 
ml-1, 0.1 mg ml-1, and 0.05 mg ml-1) can all be detected with good signal-to-noise 
ratio. 
An experiment has been conducted to assess the sensitivity limit of PA imaging in detecting 
the SNARF-PAA NPs in subsurface tissue. The SNARF-PAA NP solutions (in PBS pH 7.4) were 
placed in an optically transparent tube (1.8 mm inner diameter) which was covered by a slab of 
6-mm thick chicken breast tissue. The surface of the chicken breast was illuminated with a 
homogenous light beam with light fluence of 20 mJ cm-2 at 565-nm wavelength. The SNARF-
PAA NP solutions were diluted to different concentrations, including 0.05 mg ml-1, 0.1 mg ml-1, 
and 0.2 mg ml-1. The PA signals detected from the NP solutions are shown in Figure 2.15. At 
even very low concentration of 0.05 mg ml-1 which is 400 times dilution of the injection 
concentration, the NP solution was still detectable with a good signal-to-noise ratio over 20 dB. 
400 times of dilution was decided because we estimated that the tumor volume was around 1/400 
of the mouse body and assumed SNARF-PAA NPs were uniformly distributed in the body. 
Considering the preferential accumulation of the NPs in the tumor due to both enhanced 
permeability and retention (EPR) effect and the active tumor targeting moiety, the actually NP 
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concentrations in the mouse tumors in vivo should be higher.  
 
Hemoglobin oxygen saturation (sO2) images before the injection of SNARF-PAA NPs 
 
Figure 2.16 PA hemoglobin oxygen saturation (sO2) image in the tumor in vivo before the 
injection of SNARF-PAA NPs. PA imaging processing and analyses were performed 
by Dr. Janggun Jo. 
The quad-wavelength PA ratiometric imaging provided hemodynamic functional imaging 
including both hemoglobin oxygen saturation (sO2) and total hemoglobin concentration (THb) at 
the same time of pH imaging, as shown in Figure 2.11c and 2.11d.  We also studied the sO2 
image of the same tumor at 0 min (i.e. before the injection of SNARF-PAA NPs), as shown in 
Figure 2.16. This image at 0 min shows similar sO2 level as the image acquired at 75 minutes. 
The center area of the tumor also has relatively low oxygen saturation. 
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Quad-wavelength ratiometric calibration of the PAI system  
 
Figure 2.17 Quad-wavelength ratiometric calibration lines measured by the PAI system 
built on the Verasonics platform. The solid lines (i.e. 576 nm/565 nm, 584 nm/565 
nm, and 600 nm/565 nm) are the linear fittings of the measurements at four different 
pH levels (i.e. pH 6.2, pH 6.6, pH 7, and pH 7.4). The dashed lines are the results 
from the V312 transducer (Figure 2.10a) for comparison. The points show the 
averages of image intensity ratios with standard deviations (n=50). 
Gel phantoms (1.6-mm cylinders) contained SNARF-PAA NPs (concentration 10 mg ml-1) at 
different pH buffers (i.e. pH 6.2, pH 6.6, pH 7, and pH 7.4) were made. Each phantom was 
imaged along the cross section using the PAI system built on the Verasonics US platform at the 
four wavelengths (565 nm, 576 nm, 584 nm, and 600 nm). For the PA image at each wavelength, 
the pixel intensities in the phantom were averaged. The average PA image intensities at the three 
wavelengths (576 nm, 584 nm and 600 nm) were divided by the average PA image intensity at 
the isosbestic point (565 nm). For each ratiometric measurement at each pH level, the 
measurements from 50 images were averages and the standard deviation was calculated, as 
shown in Figure 2.17. Linear fittings of the measurements at the four pH levels were conducted, 
and the resulted calibration lines (i.e. 576 nm/565 nm, 584 nm/565 nm, and 600 nm/565 nm) 
were compared to those from the V312 transducer. The calibration lines from the two systems 
are similar. 
41 
 
2.3 Discussion 
Although the importance of pH in biological tissue, especially with respect to tumor acidosis, 
has been noted for many decades, we still lack a practical method for imaging and non-
invasively quantifying pH in biological samples in vivo. Here we presented a nanoparticle 
assisted, non-invasive, and in vivo PAI technique for quantitative pH imaging of subsurface solid 
tumors in vivo based on optical spectroscopy. The PA pH nanosensors were fabricated by 
encapsulating the SNARF-5F dye in the PAA NPs. The nanoparticle matrix serves a critical role 
in chemical imaging in vivo, protecting the sensing dye molecules from direct interactions with 
interfering proteins or enzymes as well as enabling specific targeting of tumor cells. For instance, 
direct interaction with albumin can significantly influence an indicator dye molecule’s optical 
characteristics and reduce its pH sensing capability. The experimental results from the phantoms 
and the animal model demonstrated that quad-wavelength ratiometric PAI allows a 
differentiation of the optical spectra of hemoglobin and pH-dependent SNARF-PAA NPs. As a 
result, quantitative imaging of pH without being affected by the background light absorption in 
biological tissues becomes possible. In addition, the quantification of pH is unaffected by the 
variation in the SNARF-PAA NP concentration. All these features are crucial for practical 
applications of the technique in vivo. At the same time, for pH imaging, the quad-wavelength 
PAI also allows quantitative evaluation of tumor hemodynamic properties, including blood 
volume and blood oxygenation.  
In this study, we assumed that the major chromophores in the target biological samples are 
the two forms of hemoglobin, which is true in the spectral region of 565-600 nm. In the future, 
when other chromophores may be present in the target tissue, imaging at additional wavelengths 
will be needed. However, the number of wavelengths scanned by for PAI is related to the cost of 
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the imaging system as well as the imaging speed. Currently, using a single tunable laser as the 
light source, the switching between laser wavelengths limits the imaging speed. When a multi-
wavelength light source (e.g. a system working with multiple lasers each firing at different 
wavelength) or a tunable laser enabling very fast wavelength switching becomes available, 2D 
B-scan imaging of tumor pH could be achieved at higher speed or even in real-time fashion. In 
the future, 3D imaging of the tumor microenvironment is also possible, either by performing a 
scan of a linear array ultrasound probe or by using a more advanced 2D array ultrasound probe. 
The commercially available SNARF-5F is considered as a long-wavelength fluorescent pH 
indicator, and has been well-developed and widely used for fluorescence based measurement of 
pH in vitro. This is the reason that the SNARF-5F was employed to build the pH sensing PAA 
NPs in this proof-of-principle study. Working in the spectral range of 565-600 nm, quantitative 
imaging of pH by quad-wavelength ratiometric PA measurement can be achieved with 
satisfactory accuracy in subsurface tissue at a depth up to 6 mm. We have further estimated the 
error in pH quantification due to the optical attenuation at different wavelengths for quad-
wavelength PA ratiometric imaging, as described in Figure 2.14. As expected, the error becomes 
larger when the imaging depth increases. However, at 6-mm depth in an optically scattering 
tissue, the error caused by the optical attenuation was less than 0.16 pH. This error could be 
further reduced by compensating the wavelength-dependent optical attenuation when simulating 
the point-by-point pH levels. In another experiment, as described in the Figure 2.15, we have 
further assessed the sensitivity limit of PA imaging in detecting the SNARF-PAA NPs in 
subsurface tissue. At the depth of 6 mm in an optically scattering tissue, a SNARF-PAA NP 
solution at very low concentration of 0.05 mg ml-1 can still be detected with a good signal-to-
noise ratio (SNR) over 20 dB. The 6-mm depth achieved by PA pH imaging is one order of 
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magnitude deeper than that accessible by fluorescence microscopy. With the current imaging 
depth, many clinical applications on relatively superficial tumors become possible, such as head 
and neck cancer, colorectal cancer, and cervical cancer, which are all associated with an acidic 
tumor microenvironment39-41. For imaging of deeper tumors, pH indicating dyes that absorb at 
longer optical wavelengths (e.g. 650-950 nm) will be needed so as to further improve the optical 
penetration. One advantage of our PAA NP system is that replacing the dye inside the NP is quite 
simple. 
 
2.4 Conclusion 
In oncology, low pH (acidosis) is believed to influence cell metabolism and tumor 
progression. We believe that our imaging technique has a high potential for cancer research by 
answering some important general biological or pathological questions. With its many 
advantages, this non-invasive and non-ionizing imaging technique is also highly translational, 
and may enable image-guided treatment of cancer in clinical settings. It has been reported that 
the cytotoxicity, i.e. efficacy, of certain drugs such as daunorubicin, doxorubicin, and 
mitoxantrone are reduced under acidic condition; while other drugs, such as chlorambucil, 
cyclophosphamide, and 5-fluorouracil, show higher cytotoxicity at lower pH42. Therefore, being 
capable of quantifying the pH level of the tumor microenvironment using imaging technology 
may enable instant optimization of chemotherapy and facilitate personalized treatment for cancer 
patients. In addition, this nanotechnology based imaging method can readily be applied to other 
diseases where pH plays an important role. The PA nanosensors described in this work can also 
be developed for other biologically relevant chemical analytes and thus functional imaging of 
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other physiological parameters (e.g. hyperkalemia or hypoxia) can be realized using the chemical 
PAI approach. On top of the sensing capability, other therapeutic agents (i.e. chemotherapy 
and/or photo-activated therapy) can also be incorporated into such a multifunctional 
nanoparticle34, 35, turning them into theranostic nanoparticles. Our PA chemical imaging method 
can thus broaden the field of nano-diagnostics and even combine it with nano-therapeutics. 
 
2.5 Methods 
Chemicals 
All chemicals were purchased from Sigma Aldrich or ThermoFisher Scientific unless 
otherwise noted. 
 
Synthesis of SNARF-PAA NP and F3 surface modification 
SNARF-5F has a pKa ~7.2 which is optimal for sensing near neutral physiological pH. The 
SNARF-5F was encapsulated by polyacrylamide polymers crosslinked by glycerol 
dimethacrylate (GDMA) to produce SNARF-PAA NPs29. All reactions were performed in the 
dark. Monomer solution containing 1.3 mL of Millipore water, SNARF-5F 5-(and-6)-carboxylic 
acid (SNARF) (3mg in 100 μL DMSO), Acrylamide (9.7 mmol), 3-
(aminopropyl)methacrylamide hydrochloride salt (APMA) (0.3 mmol), and the crosslinker, 
GDMA, (2 mmol) was added and emulsified in a surfactant solution of AOT (1.6g) and Brij L4 
(3.3 mL) in Hexane (45 mL). The polymerization was initiated by addition of N,N,N′,N′-
tetramethylethylenediamine (TEMED) (100 μL) and 10% (w/w) Ammonium Persulfate (100 
μL). A small percentage of APMA was introduced as another monomer to provide primary 
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amines used for later surface modification. The reaction was allowed to stir for 2 hours and 
hexane was removed by rotary evaporation. The prepared nanoparticles were washed with 
ethanol and water with Amicon Filter Cell using a 300 kDa filter, and then lyophilized. Although 
slight leaching of the dye was observed initially, during purification, there was no leaching 
during further steps of the synthesis. The surface of the SNARF-PAA NP was PEGylated and 
conjugated with tumor homing F3 peptides, following previous protocols32. The cancer targeting 
capability of our PAA NPs conjugated with F3 peptides has been extensively studied30, 43, 44. Bi-
functional Polyethylene Glycol (MAL-PEG-SCM, 2kDa, Creative PEGWorks) (4 mg) was added 
into SNARF-PAA in PBS (pH 7.4) (50 mg per 2.5mL). After 30 min of stirring, it was washed 
with PBS using Amicon Ultra Centrifugal Filter (100 kDa) and F3 Peptide 
(KDEPQRRSARLSAKPAPPKPEPKPKKAPAKKC, RS Synthesis) (11mg) was added and 
stirred overnight. Cysteine (0.63 mg) was added and stirred for 2 hours to deactivate unreacted 
maleimide groups. The NP solution was washed with water and lyophilized. Blank PAA NPs 
were synthesized in the same method without SNARF-5F. The dye loadings of the nanoparticles 
were approximately 2.4 nmol of SNARF-5F per 1 mg of NPs. The SNARF-PAA NP was 
characterized by UV-VIS spectroscopy (UV-1601 Spectrometer, Shimadzu), fluorescence 
spectroscopy (FluoroMax-3, Horiba), and Dynamic Light Scattering instrument (DLS, Delsa 
Nano C particle analyzer instrument, Beckman Coulter). 
 
Study of free SNARF-5F and SNARF-PAA NP interactions with albumin using UV-
VIS 
Different pH buffers were prepared by mixing different amounts of NaOH and KH2PO4. The 
pH level of each sample was confirmed using the micro pH electrode. To study the free SNARF-
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5F and the SNARF-PAA NP interactions with proteins, human serum albumin (HSA) (4 mg ml-) 
was introduced into different pH buffers containing either free SNARF-5F or SNARF-PAA NPs 
(2 mg ml-1). Free SNARF-5F dye concentration was equivalent to that loaded in SNARF-PAA 
NPs. The possible change in the optical absorption property of each sample containing either free 
SNARF-5F or SNARF-PAA NPs caused by interaction with HSA was measured using the UV-
1601 Spectrometer (Shimadzu). 
 
Imaging system 
PAI of phantoms and animals in vivo was performed using our US and PA dual imaging 
system built on a commercially available research US platform (V1, Verasonics, Redmond, WA) 
and a linear array probe working at a central frequency of 11.25 MHz (CL15-7, Philips, Andover, 
MA,). The laser light was from an optical parameters oscillator (Slopo, Continuum, Santa Clara, 
CA) pumped by an Nd:YAG laser (Surelite, Continuum, Santa Clara, CA) working at a 10 Hz 
pulse repetition rate and with a pulse width of 5 ns. The details of this imaging system have been 
introduced in our former publication45. Powered by a GPU card, this dual-modality system can 
acquire PA and US images from the same sample at the same time, both in real-time fashion with 
a frame rate of 10 Hz (i.e. the laser pulse repetition rate). The fast imaging speed is highly 
valuable for functional PA imaging, because multi-wavelength images need to be acquired within 
a relatively short time period before functional parameters potentially change. The quantified 
spatial resolution for PAI are 226 μm lateral and 166 μm axial at a depth of 6 mm. The light 
beam on the sample surface formed a rectangle shape with a size of 1.5 cm by 3 cm. The light 
fluence was less than 20 mJ cm-2 which, according to the ANSI standard, is safe for human skin. 
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The good sensitivity of this system in imaging SNARF-PAA NPs in subsurface tissue has been 
validated, as the details shown in Figure 2.15. At a very low concentration of 0.05 mg ml-1 (400 
times dilution of the injection concentration), an SNR over 20 dB was achieved in imaging 
SNARF-PAA NPs at 6-mm depth in optically scattering tissue. 
 
Method of dual-wavelength ratiometric photoacoustic pH measurement 
To obtain the calibration line for dual-wavelength ratiometric PA measurement of pH, 
SNARF-PAA NP solutions (concentration 20 mg ml-1) with different pH levels from 5.8 to 7.7 
(0.1 pH interval) were measured at two wavelengths (i.e. 565 nm and 600 nm). The pH level of 
each solution was confirmed by the pH electrode. Illuminated by the laser beam, the PA signals 
from each solution were collected by a cylindrically focused ultrasound transducer (V312, 
Panametrics). The signal amplitude at 600 nm divided by the signal amplitude at the isosbestic 
point of 565 nm gave a ratio. With ratios from three samples at each pH level (n=3), an average 
and a standard deviation were obtained.  
 
Method of quad-wavelength PA ratiometric imaging of pH 
To overcome the problem faced by dual-wavelength ratiometric PAI, a method based on PAI 
at additional wavelengths, i.e. quad-wavelength ratiometric PAI was proposed. Besides the 
original two optical wavelengths involved in dual-wavelength ratiometric imaging (i.e. 565 nm 
and 600 nm), another two additional wavelengths (i.e. 576 nm and 584 nm) were introduced to 
separate the contributions to spectroscopic PA measurement from the two forms of hemoglobin 
and the SNARF-PAA NP. The wavelength at 584 nm is an isosbestic point where HbO2 and Hb 
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have the same optical extinction coefficient. At 576 nm, the optical extinction coefficient of 
HbO2 has a local peak, enabling high sensitivity in separating the two forms of hemoglobin.  
Assuming that the main chromophores in the target sample are HbO2, Hb, and SNARF-PAA 
NP, then the PA intensity at wavelength λ can be expressed as in Equation (1):  
𝑃𝜆 = 𝑘 [𝜀𝐻𝑏𝑂2_𝜆  𝐶𝐻𝑏𝑂2 + 𝜀𝐻𝑏_𝜆  𝐶𝐻𝑏 + 𝜀𝑁𝑃_𝜆  𝐶𝑁𝑃 ],   (1) 
where k is a constant depending on experimental conditions including the Grüneisen parameter 
of the tissue, the light fluence, and the sensitivity of the imaging system. Assuming that the light 
fluence, after calibration of the output energy from the laser, are the same for all the optical 
wavelengths, k will be independent of the wavelength. This assumption holds when the optical 
wavelengths applied are close and the imaging depth is limited, as discussed in detail in Figure 
2.14. ε indicates the absorption coefficient of HbO2, Hb, or NP at wavelength λ, and C is the 
concentration of HbO2, Hb, or NP. Similar to the optical absorption of SNARF-PAA NPs at 600 
nm, the optical absorption of SNARF-PAA NPs at 576 nm or 584 nm can be expressed as a 
linear function of the optical absorption at the isosbestic point of 565 nm and the pH value: 
     𝜀𝑁𝑃_𝜆 = 𝜀𝑁𝑃_𝜆565(𝛼 ∙ pH + 𝑏)                       (2) 
where the constants α and b for each wavelength (576 nm, 584 nm, and 600 nm) can determined 
by performing ratiometric PA measurement of the SNARF-PAA NPs ex vivo. Therefore, the PA 
signal amplitudes at all the four wavelengths can be written as: 
𝑃𝜆565 = 𝑘 [𝜀𝐻𝑏𝑂2_𝜆565 𝐶𝐻𝑏𝑂2 + 𝜀𝐻𝑏_𝜆565 𝐶𝐻𝑏 +  0 ∙  pH 𝜀𝑁𝑃_𝜆565 𝐶𝑁𝑃 + 1 ∙  𝜀𝑁𝑃_𝜆565𝐶𝑁𝑃]    (3) 
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𝑃𝜆576 = 𝑘 [𝜀𝐻𝑏𝑂2_𝜆576 𝐶𝐻𝑏𝑂2 + 𝜀𝐻𝑏_𝜆576 𝐶𝐻𝑏 + 𝛼𝐼𝜆576
𝐼𝜆565
 
pH 𝜀𝑁𝑃_𝜆565 𝐶𝑁𝑃 + 𝑏𝐼𝜆576
𝐼𝜆565
 𝜀𝑁𝑃_𝜆565𝐶𝑁𝑃](4) 
𝑃𝜆584 = 𝑘 [𝜀𝐻𝑏𝑂2_𝜆584 𝐶𝐻𝑏𝑂2 + 𝜀𝐻𝑏_𝜆584 𝐶𝐻𝑏 + 𝛼𝐼𝜆584
𝐼𝜆565
 
pH 𝜀𝑁𝑃_𝜆565 𝐶𝑁𝑃 + 𝑏𝐼𝜆584
𝐼𝜆565
 𝜀𝑁𝑃_𝜆565𝐶𝑁𝑃] (5) 
𝑃𝜆600 = 𝑘 [𝜀𝐻𝑏𝑂2_𝜆600 𝐶𝐻𝑏𝑂2 + 𝜀𝐻𝑏_𝜆600 𝐶𝐻𝑏 + 𝛼𝐼𝜆600
𝐼𝜆565
 
pH 𝜀𝑁𝑃_𝜆565 𝐶𝑁𝑃 +
𝑏𝐼𝜆600
𝐼𝜆565
 𝜀𝑁𝑃_𝜆565𝐶𝑁𝑃] (6) 
The Equation (3)-(6) can be converted to matrix form: 
𝑘 ∙
[
 
 
 
 
 
 
𝜀𝐻𝑏𝑂2_𝜆565 𝜀𝐻𝑏_𝜆565 0                  𝜀𝑁𝑃_𝜆565  
𝜀𝐻𝑏𝑂2_𝜆576 𝜀𝐻𝑏_𝜆576
𝛼𝐼𝜆576
𝐼𝜆565
 
𝜀𝑁𝑃_𝜆565  𝑏𝐼𝜆576
𝐼𝜆565
 𝜀𝑁𝑃_𝜆565 
𝜀𝐻𝑏𝑂2_𝜆584 𝜀𝐻𝑏_𝜆584
𝛼𝐼𝜆584
𝐼𝜆565
 𝜀𝑁𝑃_𝜆565   𝑏𝐼𝜆584
𝐼𝜆565
 𝜀𝑁𝑃_𝜆565 
𝜀𝐻𝑏𝑂2_𝜆600 𝜀𝐻𝑏_𝜆600
𝛼𝐼𝜆600
𝐼𝜆565
 𝜀𝑁𝑃_𝜆565  𝑏𝐼𝜆600
𝐼𝜆565
 
𝜀𝑁𝑃_𝜆565 
]
 
 
 
 
 
 
[
𝐶𝐻𝑏𝑂2
𝐶𝐻𝑏
pH ∙ 𝐶𝑁𝑃
𝐶𝑁𝑃
] = [
𝑃𝜆565
𝑃𝜆576
𝑃𝜆584
𝑃𝜆600
]   (7) 
𝑘 ∙
[
 
 
 
𝐶𝐻𝑏𝑂2
𝐶𝐻𝑏
pH ∙ 𝐶𝑁𝑃 ∙ 𝜀𝑁𝑃_𝜆565 
𝐶𝑁𝑃 ∙ 𝜀𝑁𝑃_𝜆565 ]
 
 
 
=
[
 
 
 
 
 
 
𝜀𝐻𝑏𝑂2_𝜆565 𝜀𝐻𝑏_𝜆565 0         1 
𝜀𝐻𝑏𝑂2_𝜆576 𝜀𝐻𝑏_𝜆576
𝛼𝐼𝜆576
𝐼𝜆565
 
 𝑏𝐼𝜆576
𝐼𝜆565
 
𝜀𝐻𝑏𝑂2_𝜆584 𝜀𝐻𝑏_𝜆584
𝛼𝐼𝜆584
𝐼𝜆565
   𝑏𝐼𝜆584
𝐼𝜆565
 
𝜀𝐻𝑏𝑂2_𝜆600 𝜀𝐻𝑏_𝜆600
𝛼𝐼𝜆600
𝐼𝜆565
  𝑏𝐼𝜆600
𝐼𝜆565
 ]
 
 
 
 
 
 
−1
[
𝑃𝜆565
𝑃𝜆576
𝑃𝜆584
𝑃𝜆600
].        (8) 
The left side of Equation (8) as a 4×1 matrix can be computed when all the variables on the right 
side of the equation are known or can be determined by multi-wavelength PA measurements. 
Then blood sO2 and the pH level of each pixel in the imaging plane can be computed by 
  sO2 =
𝑘𝐶𝐻𝑏𝑂2
𝑘(𝐶𝐻𝑏𝑂2+𝐶𝐻𝑏)
                                (9) 
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pH =
𝑘∙𝑝𝐻∙𝐶𝑁𝑃∙𝜀𝑁𝑃_𝜆565 
𝑘∙𝐶𝑁𝑃∙𝜀𝑁𝑃_𝜆565 
  .                             (10) 
The images showing the relative distribution of total hemoglobin concentration and the relative 
distribution of the SNARF-PAA NP can be computed by 
THb = 𝑘 ∙ (𝐶𝐻𝑏𝑂2+𝐶𝐻𝑏)                                (11) 
NP = 𝐶𝑁𝑃 ∙ 𝜀𝑁𝑃_𝜆565                                (12) 
where both k and εNP_λ565 are constants. MATLAB (R2010a, Mathworks, Natick, MA) was used 
for simulation of the results from the phantoms and the animals. 
Before quad-wavelength ratiometric PAI can be performed, we first need to obtain the 
calibration lines for 576 nm and 584 nm wavelengths, respectively, in addition to the calibration 
line for 600 nm as shown in Figure 2.9b. Following the same procedure, SNARF-PAA NP 
(concentration 20 mg ml-1) with pH from 5.8 to 7.7 (0.1 pH interval) was measured at the 
wavelengths of 565 nm, 576 nm, and 584 nm. The PA signal amplitudes at 576 nm and 584 nm 
were divided by the signal amplitude at the isosbestic point of 565 nm. With measurements from 
three samples at each pH level (n=3), averages and standard deviations were obtained. The 
calibration lines here (Figure 2.10a) were obtained using the well-calibrated single-element 
V312 transducer, benefiting from its excellent receiving sensitivity. However, the calibration 
lines are independent of the detection system, and also work for the PAI system based on the 
Verasonics US platform (Figure 2.17).  
We intentionally selected the four optical wavelengths that are close so that the optical 
spectral range for quad-wavelength PA ratiometric imaging is relatively small (565-600 nm). In 
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this case, when the incident light energy on the sample surface can be calibrated for each 
wavelength, the distributions of the light fluence in the tissue can be considered similar for all 
the wavelengths. Otherwise, largely separated wavelengths can lead to significant difference in 
optical attenuation in tissue, which, if not compensated, can affect the accuracy in quantifying 
tumor pH using quad-wavelength PA ratiometric imaging. In other words, the optical spectrum 
selected needs to differentiate the optical spectra of HbO2, Hb and pH-dependent SNARF-PAA 
NPs; while the optical attenuation in tissue cannot be largely different within the selected 
spectrum. We have further studied the potential error in pH quantification due to the 
spectroscopic difference in optical attenuation in tissue, as the details shown in Figure 2.13. At a 
depth of 6 mm in optically scattering tissue, the potential error caused by the difference in optical 
attenuation over the spectral range of 565-600 nm is about 0.16 pH. This already minor error can 
be further reduced by compensating the light attenuation in the simulation. 
 
PAI on phantoms 
For the studies on phantoms, including both dual-wavelength and quad-wavelength 
ratiometric imaging, the phantoms were made from porcine gel (concentration 80g L-1). Each 
phantom contained SNARF-PAA NPs with a concentration of 20 mg ml-1, and was buffered at 
different pH levels (pH 6.6, pH 7.0, and pH 7.4). For dual-wavelength ratiometric imaging, the 
PA image of a phantom at 600 nm, after being smoothed by Gaussian filter, was divided by the 
PA image at 565 nm, which led to a pixel-by-pixel PA ratiometric image of the phantom. For 
quad-wavelength ratiometric imaging, each phantom was imaged with the four wavelengths. 
Then the 2D pH image was computed following the procedure described. To study the potential 
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error in pH imaging caused by the background optical absorption, whole blood was added in 
some phantoms with a concentration of 1% (w/w). 1% blood content is reasonable, considering 
that, as reported in a literature, the blood content in human glioma tumor ranges from 0.95 to 
2.79%46. To find out whether the pH measurement based on quad-wavelength ratiometric 
imaging is affected by the concentration of the SNARF-PAA NPs, phantoms were also made 
with different NP concentrations (2 mg ml-1, 10 mg ml-1, and 20 mg ml-1).  
 
PAI of tumor pH in a mouse model in vivo 
All the procedures on live animals were approved by the University Committee on the Use 
and Care of Animals (UCUCA) of the University of Michigan (U-M). The mice were housed at 
the U-M Medical School in the Unit for Laboratory Animal Medicine (ULAM). In total, four 
mice (5 weeks old male, Athymic nude Fox/NU, Envigo) were used. 9L rat glioma cell line 
(American Type Culture Collection) was cultured in RPMI 1640 medium supplemented with 
10% Fetal Bovine Serum (FBS) and 1% Antibiotic-antimycotic. Approximately 106 cells in 100 
μL of culture media were subcutaneously injected on the back of each mouse. Each tumor was 
allowed to grow for 2-3 weeks until its volume reached around 0.5 cc as measured using a 
caliper. 
The nude mice were anesthetized with the inhalation of 1.0-2.0% isoflurane mixing with 
oxygen. During imaging, the laser light covered the entire tumor area as well as some 
surrounding tissue. The ultrasound probe was fixed around 1 cm above the tumor. During 
imaging experiment, the body temperature of mouse was also maintained with a heating lamp. 
The SNARF-PAA NP solution (20 mg ml-1 in saline) was injected through tail-vein (250 mg NP 
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per kg body weight). The PA images were acquired before the injection (0 min), and at 15 min, 
45 min, and 75 min respectively after the injection. To improve the signal-to-noise ratio, the PA 
images acquired at each wavelength were averaged 50 times. Considering that the wavelength 
switching time was 5-10 second, the total time period for PA imaging at the four wavelengths 
was less than 60 seconds. To avoid potential motion artifact, the animal especially the tumor area 
under the scan was fixed tightly during image acquisition using a home-fabricated fixation 
device. With the images from the four wavelengths acquired, the spatially distributed NP 
concentrations and the spatially distributed pH levels were computed for each time point. For 
image pixels with weak PA signals, calculating the ratios among different wavelengths, as 
performed in quad-wavelength PA ratiometric imaging, could have large errors caused by the 
background noise. Therefore, to reduce the possible errors, a universal threshold of 6 dB above 
the background noise level was set for PA intensity images, meaning that the pixel-by-pixel 
computation of the pH level was performed only for those pixels with intensities above the 6 dB 
threshold. 
To provide a control, quad-wavelength PAI was also performed on normal tissues. For each 
mouse, the SNARF-PAA NP solution (20 mg ml-1 in saline) was subcutaneously injected into the 
thigh (50 mg NP per kg body weight). Since the distribution of the locally injected NPs in the 
thigh is relying on perfusion, instead of a single injection of a high dose, multiple spatially 
scattered injections each with smaller dose were applied aiming at achieving more homogenous 
distribution of NPs in the thigh. The PA images of the treated thigh were obtained at 10 min after 
the injection. The PA images at the four wavelengths were used to compute the spatially 
distributed pH levels in the thigh. After the imaging experiment was finished, the pH levels in the 
tumors and the thighs were measured by inserting the micro pH electrode in multiple positions in 
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the target tissues. 
 
2.6 References 
1. Adrogue, H.J. & Madias, N.E. Management of life-threatening acid-base disorders. First 
of two parts. N Engl J Med 338, 26-34 (1998). 
2. Grinstein, S., Swallow, C.J. & Rotstein, O.D. Regulation of cytoplasmic pH in phagocytic 
cell function and dysfunction. Clin Biochem 24, 241-247 (1991). 
3. Egginton, S., Taylor, E.W. & Raven, J.A. Regulation of tissue pH in plants and animals : a 
reappraisal of current techniques. (Cambridge University Press, Cambridge, UK ; New 
York; 1999). 
4. Hsu, P.P. & Sabatini, D.M. Cancer cell metabolism: Warburg and beyond. Cell 134, 703-
707 (2008). 
5. Warburg, O. On the origin of cancer cells. Science 123, 309-314 (1956). 
6. Vaupel, P., Kallinowski, F. & Okunieff, P. Blood flow, oxygen and nutrient supply, and 
metabolic microenvironment of human tumors: a review. Cancer Res 49, 6449-6465 (1989). 
7. Eil, R. et al. Ionic immune suppression within the tumour microenvironment limits T cell 
effector function. Nature 537, 539-+ (2016). 
8. Höckel, M. & Vaupel, P. Tumor Hypoxia: Definitions and Current Clinical, Biologic, and 
Molecular Aspects. Journal of the National Cancer Institute 93, 266-276 (2001). 
9. Raghunand, N. et al. Enhancement of chemotherapy by manipulation of tumour pH. Br J 
Cancer 80, 1005-1011 (1999). 
10. Tredan, O., Galmarini, C.M., Patel, K. & Tannock, I.F. Drug resistance and the solid tumor 
microenvironment. J Natl Cancer Inst 99, 1441-1454 (2007). 
11. Kato, Y. et al. Acidic extracellular microenvironment and cancer. Cancer Cell Int 13, 89 
(2013). 
12. Gallagher, F.A. et al. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-
labelled bicarbonate. Nature 453, 940-943 (2008). 
13. Gillies, R.J., Raghunand, N., Garcia-Martin, M.L. & Gatenby, R.A. pH imaging. A review 
of pH measurement methods and applications in cancers. IEEE Eng Med Biol Mag 23, 57-
64 (2004). 
14. Longo, D.L. et al. A general MRI-CEST ratiometric approach for pH imaging: 
demonstration of in vivo pH mapping with iobitridol. J Am Chem Soc 136, 14333-14336 
(2014). 
15. Rottenberg, D.A. et al. In vivo measurement of brain tumor pH using [11C]DMO and 
positron emission tomography. Ann Neurol 17, 70-79 (1985). 
16. Vavere, A.L. et al. A novel technology for the imaging of acidic prostate tumors by positron 
emission tomography. Cancer Res 69, 4510-4516 (2009). 
17. Berezin, M.Y. et al. Near-infrared fluorescence lifetime pH-sensitive probes. Biophys J 100, 
2063-2072 (2011). 
18. Lee, H., Berezin, M.Y., Tang, R., Zhegalova, N. & Achilefu, S. Pyrazole-substituted near-
infrared cyanine dyes exhibit pH-dependent fluorescence lifetime properties. Photochem 
55 
 
Photobiol 89, 326-331 (2013). 
19. Gilson, R.C. et al. Protonation and Trapping of a Small pH-Sensitive Near-Infrared 
Fluorescent Molecule in the Acidic Tumor Environment Delineate Diverse Tumors in Vivo. 
Mol Pharm 12, 4237-4246 (2015). 
20. Chen, Q. et al. A Self-Assembled Albumin-Based Nanoprobe for In Vivo Ratiometric 
Photoacoustic pH Imaging. Adv Mater 27, 6820-6827 (2015). 
21. Xu, M.H. & Wang, L.H.V. Photoacoustic imaging in biomedicine. Rev Sci Instrum 77 
(2006). 
22. Wang, X. et al. Noninvasive laser-induced photoacoustic tomography for structural and 
functional in vivo imaging of the brain. Nature biotechnology 21, 803-806 (2003). 
23. Wang, L.V. Multiscale photoacoustic microscopy and computed tomography. Nature 
photonics 3, 503-509 (2009). 
24. Yuan, J. et al. Real-time photoacoustic and ultrasound dual-modality imaging system 
facilitated with graphics processing unit and code parallel optimization. Journal of 
Biomedical Optics 18, 86001-86001 (2013). 
25. Chatni, M.R. et al. Functional photoacoustic microscopy of pH. Journal of biomedical 
optics 16, 100503 (2011). 
26. Kimbrough, C.W. et al. Targeting Acidity in Pancreatic Adenocarcinoma: Multispectral 
Optoacoustic Tomography Detects pH-Low Insertion Peptide Probes In Vivo. Clin Cancer 
Res 21, 4576-4585 (2015). 
27. Guha, S., Shaw, G.K., Mitcham, T.M., Bouchard, R.R. & Smith, B.D. Croconaine rotaxane 
for acid activated photothermal heating and ratiometric photoacoustic imaging of acidic 
pH. Chem Commun (Camb) 52, 120-123 (2016). 
28. Horvath, T.D., Kim, G., Kopelman, R. & Ashkenazi, S. Ratiometric photoacoustic sensing 
of pH using a "sonophore". Analyst 133, 747-749 (2008). 
29. Ray, A., Yoon, H.K., Koo Lee, Y.E., Kopelman, R. & Wang, X. Sonophoric nanoprobe 
aided pH measurement in vivo using photoacoustic spectroscopy. Analyst 138, 3126-3130 
(2013). 
30. Orringer, D.A. et al. In vitro characterization of a targeted, dye-loaded nanodevice for 
intraoperative tumor delineation. Neurosurgery 64, 965-971; discussion 971-962 (2009). 
31. Winer, I. et al. F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that 
targets both murine and human ovarian tumor endothelial cells in vivo. Cancer research 
70, 8674-8683 (2010). 
32. Nie, G. et al. Hydrogel nanoparticles with covalently linked coomassie blue for brain tumor 
delineation visible to the surgeon. Small 8, 884-891 (2012). 
33. Reddy, G.R. et al. Vascular targeted nanoparticles for imaging and treatment of brain 
tumors. Clin Cancer Res 12, 6677-6686 (2006). 
34. Koo, Y.E. et al. Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv 
Rev 58, 1556-1577 (2006). 
35. Koo, Y.E. et al. Photonic explorers based on multifunctional nanoplatforms for biosensing 
and photodynamic therapy. Appl Opt 46, 1924-1930 (2007). 
36. Buck, S.M. et al. Optochemical nanosensor PEBBLEs: photonic explorers for bioanalysis 
with biologically localized embedding. Curr Opin Chem Biol 8, 540-546 (2004). 
37. Burtis, C.A. & Ashwood, E.R. Tietz Textbook of Clinical Chemistry, Edn. 3rd. (Saunders, 
1999). 
56 
 
38. Jacques, S.L. Optical properties of biological tissues: a review. Physics in Medicine and 
Biology 58, R37 (2013). 
39. Loja, M.N. et al. Optical molecular imaging detects changes in extracellular pH with the 
development of head and neck cancer. Int J Cancer 132, 1613-1623 (2013). 
40. Hulikova, A., Vaughan-Jones, R.D. & Swietach, P. Dual role of CO2/HCO3(-) buffer in the 
regulation of intracellular pH of three-dimensional tumor growths. J Biol Chem 286, 
13815-13826 (2011). 
41. Anderson, M., Moshnikova, A., Engelman, D.M., Reshetnyak, Y.K. & Andreev, O.A. 
Probe for the measurement of cell surface pH in vivo and ex vivo. Proc Natl Acad Sci U S 
A 113, 8177-8181 (2016). 
42. Chen, L.Q. & Pagel, M.D. Evaluating pH in the Extracellular Tumor Microenvironment 
Using CEST MRI and Other Imaging Methods. Advances in Radiology 2015, 206405 
(2015). 
43. Winer, I. et al. F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that 
targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res 70, 
8674-8683 (2010). 
44. Nie, G. et al. Hydrogel nanoparticles with covalently linked coomassie blue for brain tumor 
delineation visible to the surgeon. Small 8, 884-891 (2012). 
45. Yuan, J. et al. Real-time photoacoustic and ultrasound dual-modality imaging system 
facilitated with graphics processing unit and code parallel optimization. J Biomed Opt 18, 
86001 (2013). 
46. Jain, R. et al. Quantitative estimation of permeability surface-area product in astroglial 
brain tumors using perfusion CT and correlation with histopathologic grade. AJNR Am J 
Neuroradiol 29, 694-700 (2008). 
 
57 
 
 
 
Chapter 3: Photoacoustic and Fluorescence Potassium Imaging 
 
This chapter has been adapted from the following publications with minor modifications: 
Lee, C. H.; Folz, J.; Zhang, W.; Jo, J.; Tan, J.; Wang, X.; Kopelman, R., “Ion-selective 
nanosensor for photoacoustic and fluorescence imaging of potassium", Analytical Chemistry, 
2017, 89 (15), 7943-7949. 
Lee, C. H.; Folz, J.; Zhang, W.; Jo, J.; Tan, J.; Wang, X.; Kopelman, R., “Correction to ion-
selective nanosensor for photoacoustic and fluorescence imaging of potassium", Analytical 
Chemistry, 2017, 89 (24), 13674-13674. 
 
 
Figure 3.0 Graphical abstract 
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3.1 Introduction 
The analysis of complex ex vivo biological fluids, such as whole blood or urine, has been 
one of the most valuable diagnostic tools in clinical chemistry, where much use is made of ion 
selective electrodes (ISEs).1 The more recent alternative to ISEs, the ion selective optodes (ISOs), 
were originally ion selective bulk optodes - a type of electrolyte sensor composed of lipophilic 
sensing components embedded in lipophilic materials that provided colorimetric detection of the 
sensed ions.1-4 A cation selective bulk optode senses the analyte cation through the competing 
equilibrium between H+ and the analyte.1-4 As the analyte binds to the lipophillic ionophore in 
the sensing matrix, the H+ from the lipophillic chromoionophore (a pH indicator dye), in that 
sensing matrix, is exchanged with the analyte cation, so as to maintain the equilibrium between 
the media inside and outside the optode. The ratio between protonated and unprotonated 
chromoionophore, derived from the optical spectra, correlates with the analyte concentrations at 
fixed pH values. To achieve equivalent information inside live cells, in vitro, the ISOs had to be 
miniaturized, i.e, to the minute volumes covering optical fiber nano-tips,5 or contained in 
nanoparticle-sensors (called NanoPEBBLEs).6-26 With such miniaturization, the traditional 
optical absorbance based detection is impractical, and thus these ISOs had to be adapted to work 
in a fluorescence based mode, as nano-optodes, using fluorescence microscopy. Here we extend 
their capabilities, so as to also work as ISPAOs (ion-selective photo-acoustic optodes). 
As pointed out above, optical ion sensors (or optodes) can be utilized by either absorbance 
or fluorescence based spectroscopy, depending on the design of the sensors and their application. 
Information acquired through optical spectroscopy allows accurate chemical sensing at a given 
location. However, the performance of such optodes has to compete with that of the “gold 
standard” of ion-selective electrodes (ISEs) for in vivo or ex vivo studies. A key advantage of 
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using optodes over ISEs is their potential to generate non-invasive chemical imaging, in vitro as 
well as in vivo. To generate chemical images using optically induced nano-sensors, one of two 
imaging modalities (fluorescence imaging and photoacoustic imaging) can be applied. 
Fluorescence imaging has already been applied to in vivo chemical, ion-selective, imaging.27 
However, as the imaging depth increases, not only does the signal-to-noise ratio decrease 
drastically, but also the spatial resolution degrades, as a result of the overwhelming scattering of 
light in tissues. As an alternative technology, photoacoustic (PA) imaging overcomes the above 
limitations of fluorescence imaging, while still keeping the high sensitivity in imaging the optical 
contrast agents.27-32 The absorption of pulsed light by the molecules of the optical contrast agents 
is transferred into thermo-elastic expansion of tissue and then detected through ultrasound, with 
little scattering by tissues, thus significantly enhancing the spatial resolution when imaging 
objects beyond the sample’s surface.  
Here, a bimodal nanosensor (NS) has been prepared for K+ as the target ion (called K+ NS), 
which can be applied for both fluorescence and PA imaging modalities, i.e., as ISO or ISPAOs. 
The potassium ion, K+ is one of the major biological cations; it is involved in controlling 
numerous physiological processes, such as enzyme activation, maintaining pH, regulation of 
blood pressure, as well as in nerve and muscle signal transmission. Just recently, Eil et al. 
reported that the  typical  elevation of extracellular K+ concentration (5 to 10 folds increase) 
in the tumor microenvironment led to the suppression of the activity of immune cells.33 
Immunotherapy of tumors has been considered as one of the most promising avenues of cancer 
therapy, outdoing the traditional avenues of radiation- and chemo-therapy. Thus understanding 
the immune suppression mechanism due to abnormally high extracellular K+ concentration 
(local hyperkalemia) created by the tumor is of high biological interest and may have a large 
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impact on research as well as in the clinic.  
This bimodal K+ sensing nanosensor (K+ NS) is prepared with primary amine groups on the 
nanoparticle’s surface, which can be used for surface modification, such as cell-specific targeting 
for in vivo applications.34-36 Another potential usage of the primary amine groups is demonstrated 
by conjugating a near infrared (NIR) absorbing/fluorescence reference dye, so as to achieve an 
NIR absorbing nanosensor, which is preferable for in vivo studies, in order to minimize tissue 
light scattering during optical imaging. The prepared K+ NS shows an excellent response to 
biologically relevant K+ concentration changes (from extracellular 5 mM to intracellular 150 
mM values),37 while remaining silent towards other biologically relevant cations in that 
concentration range. The K+ NS’s response to K+ concentrations is demonstrated here by using 
UV-VIS spectroscopy, fluorescence spectroscopy and PA spectroscopy, as well as by PA imaging.  
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3.2 Results and discussion 
K+ sensing nanosensor (K+ NS) preparation and its response to different [K+] 
 
Figure 3.1 Nanosensor preparation and sensing schematic. (a) The K+ NS is prepared in 
two steps. i. DCM evaporation via vacuum and rehydration. ii. Free radical 
polymerization. The nanosensor matrix contains DOS and polybutylmethacrylate 
(depicted as background). (b) Absorption spectra of K+ NS at different 
concentrations of potassium (from 10 μM to 1 M). At low [K+], the absorbance at 
660 nm (depicted as blue dashed line in each spectrum) is much higher than the 
absorbance at 540 nm (depicted as pink dashed line in each spectrum). At high [K+], 
the absorbance at 660 nm is much lower than the absorbance at 540 nm. 
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Figure 3.2 Photo and absorbance spectra of the K+ NS at different K+ concentrations.  
.  
Figure 3.3 Determining Primary amine group availability by using Fluorescamine assay 
(390 nm ex). An analogue batch of K+ NS without F68-amine was prepared (labeled 
“K+ NS without amine”). Into 0.3mg/mL in PBS pH 7.4, 50 μL of fluorescamine 
solution (3mg/mL in DMSO) was added and left at room temperature for 10 min. 
“K+ NS without Fluorescamine” is just K+ NS fluorescence without addition of 
fluorescamine with 390 nm excitation. “PBS” indicates just fluorescamine and PBS 
pH 7.4. 
The K+ NS was prepared via regular micelle formation using Pluronics (Figure 3.1a). Each of 
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the self-assembled micelles contains all of the hydrophobic sensing components including acrylic 
monomers. The acrylic monomers in the core of the nano-sized micelles were polymerized via free 
radical polymerization to form the K+ NS. Micelles are prone to fall apart below the critical micelle 
concentration. Thus, acrylic polymerization makes the core of the matrix more rigid, allowing the 
sensor to be more stable in biological settings. The K+ NS exhibited an average size of around 60 
nm when measured by dynamic light scattering. The sensor shows direct colorimetric changes with 
differing potassium concentrations (Figure 3.2). The primary amine group availability on the K+ 
NS is confirmed by fluorescamine assay (Figure 3.3). Fluorescamine reacts with primary amines 
becoming fluorescence. The fluorescence of fluorescamine in K+ NS was around 2 folds higher 
than the fluorescence of fluorescamine in K+ NS without primary amine availability. Figure 3.1b 
shows absorption spectra of the K+ NS at different K+ concentrations. As the K+ concentration 
increases, the chromoionophore inside the K+ NS gets deprotonated (540 nm peak increases and 
660 nm peak decreases), and vice versa. The ratio between two sensing peaks (540 nm and 660 
nm) is used for calibration in the later studies. 
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K+ NS calibration and its selectivity with respect to other cations 
 
Figure 3.4 Characterization of the K+ NS using UV-VIS spectroscopy. (a) Calibration 
curve of K+ NS with protonation degree and log of potassium concentration by using 
the peak intensity ratios of the 540nm absorbance and 660nm absorbance of the K+ 
NS in a pH 7.4 Tris-buffer (10 mM).3 The selectivity of the K+ NS in comparison to 
other biological relevant cations (K+, Na+, Ca2+, and Mg2+). (b) The sensitivity of the 
K+ NS to K+ with and without Na+ background (150 mM). 
 
Figure 3.5 Reversibility of the K+ NS. Into the stirring K+ NS solution, potassium was 
added or diluted by adding extra solvent. The measurement was done using 
fluorescence spectrometer (540 nm ex/625nm em). 
Both sensing peaks can be used to compute the calibration curve between protonation degree 
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and log of [K+]. The protonation degree was calculated based on previously described methods 
using two sensing peaks.3 The sensing component ratios were experimentally found to give a 
maximum change from 1 mM to 100 mM of K+ concentrations (Figure 3.4). It was experimentally 
determined that the dynamic range of the sensor was influencing by the ratios between the sensing 
components. For example, a sensor made with low molar amounts of potassium ionophore III 
compared to chromoionophore I has optimal sensing range at lower potassium concentrations. 
The K+ NS is capable of sensing outside of the range (1 μM to 1 M), but absorbance changes 
at the sensing peaks are not as drastic as the 1 mM to 100 mM range. Although the potassium 
ionophores inside the optodes are designed to have strong binding affinities to certain ions, binding 
other ions that have similar sizes and properties cannot be completely avoided. The K+ NS was 
tested for its selectivity compared to other biologically relevant cations (Figure 3.4a, Na+, Ca2+, 
and Mg2+). The K+ NS only starts to respond to Na+, Ca2+ and Mg2+ concentrations higher than 10 
mM while the sensor response in 100 μM of K+. The sensor’s selectivity of potassium over other 
cations is a few orders of magnitude higher. The responses of the K+ NS from Ca2+ and Mg2+ are 
negligible since typical extracellular Ca2+ and Mg2+ concentrations are around 2.5 mM and 2 mM, 
respectively.38 On the other hand, Na+ is one of the most abundant cations in biological systems 
along with K+ and sodium’s typical extracellular concentration is around 140 mM.37 In Figure 
3.4b, the K+ NS still possesses its sensing capability to potassium even with high background Na+ 
concentration (150 mM). The background interference of sodium causes the calibration curve to 
shift a little bit, but similar trend has already been observed in ISOs and ISEs.1 Thus, satisfactory 
calibrations can be generated in presence of other competing cations so as to measure K+ in 
complex biological fluids. The sensor is fully reversible and can respond to local potassium 
changes within a few seconds (Figure 3.5). 
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K+ NS Calibration by Photoacoustic (PA) Spectroscopy 
 
Figure 3.6 Characterization of the K+ NS using photoacoustic spectroscopy. (a) 
Exemplary absorbance spectra of K+ NS at 2 mM [K+] (black) and 200 mM [K+] 
(red). Two sensing peaks are indicated as dashed lines (540 nm as pink and 660 nm 
as blue). (b) Exemplary PA signals of the K+ NS with 540 nm excitation. Purple line 
is PA signal of K+ NS at 2 mM [K+] with 540 nm excitation. Red line is PA signal of 
K+ NS at 200 mM [K+] with 540 nm excitation. (c) Exemplary PA signals of the K+ 
NS with 660 nm excitation. Navy line is PA signal of K+ NS at 2 mM [K+] with 660 
nm excitation. Blue line is PA signal of K+ NS at 200 mM [K+] with a 660 nm 
excitation. (d) Photoacoustic calibration curve of K+ NS using the ratio (PA signal 
intensity at 540 nm divided by the PA signal intensity at 660nm) from 1 mM to 200 
mM [K+]. The PA ratios show logarithmic relationship with potassium concentrations 
in the absence (black circle) and presence (blue triangle) of 150 mM [Na+].  
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Figure 3.7 Examples of raw PA signals at different potassium concentrations. 
The photoacoustic effect correlates with the absorbance characteristics of the optical contrast 
agent.29 Figure 3.6a shows two absorption spectra of the K+ NS in two different potassium 
concentrations (2 mM and 200 mM). As described, the absorbance at 540 nm increases and 
absorbance at 660 nm peak decreases as potassium concentration increases. Figure 3.6b and 
Figure 3.6c show the exemplary PA signals of K+ NS in phantoms at different potassium 
concentrations. As potassium concentration increases from 2 mM to 200 mM, the PA signal 
intensity increases when excited with 540 nm (Figure 3.6b). On the other hand, PA signal intensity 
decreases as the potassium increases when excited with 660 nm (Figure 3.6c). Examples of raw 
PA signals at other potassium concentrations are shown in Figure 3.7. The sensor’s absorption 
properties can be also detected through PA spectroscopy. The ratio between the intensities of PA 
spectra at two excitations (540 nm and 660 nm) gave the calibration curve (Figure 3.6d). Here, 
we directly plotted the ratio between two excitations to form the calibration curve. The PA ratio of 
the 540 nm over the 660 nm excitations shows a logarithmic relationship with the K+ 
concentrations that we have tested (1 mM to 200 mM) in phantoms. From the absorbance 
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calibrations (Figure 3.4b), it is evident that the influence of the sodium background (150 mM) 
cannot be neglected. The PA ratios derived from the 540 nm and the 660 nm excitations were 
generated in the presence of physiological sodium concentrations (150 mM) and still formed 
logarithmic relationship with the potassium concentrations. Evidently, the sensitivity of the K+ NS 
has been lowered due to the sodium interference. However, the typical extracellular potassium 
concentration is ~ 5mM while the tumor extracellular potassium concentration has been reported 
to be 5 to 10 folds higher.33 The K+ NS can still differentiate between 4 mM and 20 mM, as shown 
in the calibration curve. 
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K+ NS Response to Photoacoustic (PA) Imaging 
 
Figure 3.8 Photoacoustic imaging of phantoms containing K+ NS at different [K+], 
labeled below each image (2mM. 10mM, 100mM, and 200mM). Black dashed circle 
indicates where the K+ NS solutions are located in the phantom. (a) “PA540” is PA 
images of phantoms with a 540nm excitation. (b) “PA660” is a PA image of phantoms 
with a 660nm excitation.(c) Ratiometric photoacoustic images (540 nm over 660 nm) 
of phantoms containing K+ NS at different [K+], as labeled below each image (2mM. 
10mM, 100mM, and 200mM). PA imaging processing was performed by Dr. Janggun 
Jo. 
The PA images of the four different K+ concentrations (2 mM, 10 mM, 100 mM, and 200 mM) 
were taken simultaneously. Two images were taken with 540 nm (Figure 3.8a) excitation and 660 
nm excitation (Figure 3.8b). Both Figure 4a and 4b do not show any specific trend at different 
potassium concentrations. Because a diverging lens was used to guide the laser pulse to the entire 
phantom, the power of the laser was not uniformly distributed among samples. The ratiometric PA 
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image (Figure 3.8c) shows clear differences between 2 mM, 10 mM, and 100 mM of potassium 
(Figure 3.8c). At concentrations 100 mM and 200 mM, the ratiometric PA intensities from the 
image do not differ too much, indicating that the sensor has almost reached its saturation near 200 
mM. The results suggest that the sensor is applicable in PA imaging. 
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Utilization of primary amine groups on K+ NS for Near-Infrared Absorption/Emission 
(NIR-K+ NS) 
 
Figure 3.9 Optical and Sensing properties of NIR-K+ NS. (a) Schematic of NIR-K+ NS 
preparation. (b) Absorbance spectra of NIR K+ NS at different K+ concentrations (10 
μM to 1 M). (c) Calibration curve of K+ NS with protonation degree vs. log potassium 
concentration, by using the peak intensity ratios of the sensing 660 nm absorbance 
and the reference 800 nm absorbance of the NIR-K+ NS, in a pH 7.4 Tris-buffer.3 (d) 
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Fluorescence emission spectra (540 nm excitation/660 nm emission) of NIR K+ NS 
at different K+ concentrations (10 μM to 1 M). The spectra were normalized by 
potassium independent NIR fluorescence (760 nm excitation/820 nm emission, data 
not shown). (e) Calibration curve of K+ NS with deprotonation degree vs. log 
potassium concentration, by using the potassium dependent sensing emission (620 
nm to 700 nm emission) and potassium independent reference emission (800 nm to 
840 nm emission) of the NIR-K+ NS, in a pH 7.4 Tris-buffer.3 
One of the unique features that the K+ NS possesses is the molecular engineering availability 
using a primary amine. Primary amine groups can be utilized for surface modification to conjugate 
both targeting moieties and reference dyes. Targeting moieties allow the nanoparticle to actively 
home in on a certain type of cells, e.g. cancer cells, giving the nanoparticle its cancer targetability 
in vivo.34, 36 As for the PA imaging, the K+ NS do not need a secondary reference dye because the 
chromoionophore already has two sensing peaks, the ratio of which can be used as an internal 
reference. However, the K+ NS has only a single emission (~660 nm). One solution to this issue is 
by conjugating onto the K+ NS nanoparticle matrix another potassium independent reference dye 
that absorbs at a higher wavelength (i.e., NIR-797), so as to acquire NIR absorbing K+ NS. 
Generally, NIR wavelengths are preferred for light sources used for in vivo studies, as this 
minimizes both potential autofluorescence and the ubiquitous Raleigh light scattering, thereby 
allowing deeper penetration into biological tissues. Having primary amine groups on the surface 
of the K+ NS provides much flexibility for modifications of the sensor. We conjugated an NIR 
absorbing dye that is insensitive to K+ (NIR-797) onto the surface of the K+ NS (giving NIR-K+ 
NS, Figure 3.9a). Figure 3.9b shows the absorption spectra of the NIR-K+ NS at different K+ 
concentrations. As shown, the NIR absorbance at 800 nm can be used as the reference absorbance 
while that at 660 nm can still be used as the sensing peak. Figure 3.9c shows a calibration curve, 
plotting the protonation degree (using 660 nm for sensing and 800 nm for reference)3 vs. log [K+]. 
The absorbance based characterization shows no significant difference in the dynamic sensing 
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range of this modified sensor, compared to the original K+ NS.  
Interestingly, the fluorescence of the NIR-K+ NS has quite a significantly different sensing 
range than the absorbance (Figure 3.9d and Figure 3.9e). The fluorescence of the NIR-K+ NS 
gives the most drastic changes from 20 mM to 1M potassium (Figure 3.9e). This sensing range 
suites the intracellular potassium monitoring (typical intracellular potassium concentration is about 
150 mM37 while that of the sodium concentration is about 10 mM12). When the majority of the 
absorbance of K+ NS is at 660 nm (i.e. low [K+]), the fluorescence at 660 nm is low. When the 
majority of the absorbance of K+ NS is at 540 nm (i.e. high [K+]), the fluorescence at 660 nm is 
significantly higher. The chromoionophore, which is essentially a pH indicator, stays mostly 
protonated in the absence of potassium and becomes deprotonated in the presence of potassium. 
In the fluorescence calibration, the degree of protonation is only dictated by the deprotonated 
sensing peak (540 nm excitation), thus, forming an opposite trend from that of the absorbance 
calibration.  
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Fluorescence imaging of K+ NS 
 
Figure 3.10 Fluorescence images of HeLa cells incubated with K+ NS (10x). (a) K+ NS 
without primary amine groups. (b) K+ NS-with amine groups. (c) F3 peptide 
modified K+ NS. 
Another potential application of the primary amine groups for the K+ NS is surface 
modification with targeting moieties, such as tumor homing F3 peptide34, 35 and cardiac myoctye 
homing CTP36. Previous in vivo studies indicate that F3 peptide modified nanoparticles show an 
increased retention time and target tumors significantly better than non-targeted nanopraticles.34, 
35 The K+ NS was surface modified with F3 peptide and fluorescence images were taken to monitor 
the uptake of the nanosensor by the cancer cells. Figure 3.10 shows the fluorescence images of 
the cancer cells incubated with different types of the nanosensors. Figure 3.10a was incubated 
with K+ NS without primary amine groups, Figure 3.10b was incubated with K+ NS containing 
primary amine groups, and Figure 3.10c was incubated with F3 peptide modified K+ NS (F3-K+ 
NS). 
The surfaces of the K+ NS without primary amine groups are essentially PEGylated surfaces, 
making it least favorable for the uptake by the cancer cells (Figure 3.10a). On the other hand, the 
surface of the K+ NS containing primary amine groups are positively charged and can be attracted 
by the negatively charged cellular membrane, leading to the highest uptake by the cancer cells 
(Figure 3.10b). During the surface modification with F3 peptide, the K+ NS is essentially 
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PEGylated; thus, the surface charge is slightly neutralized compared to the unmodified K+ NS 
(Figure 3.10c). The cellular uptake of the K+ NS suggests that intracellular potassium imaging can 
indeed be accomplished through fluorescence imaging. 
 
3.3 Conclusion 
We report, for the first time to the best of our knowledge, an ion-selective nanosensor enabled 
through PA imaging. Furthermore, this sensor is bimodal, enabling also fluorescence-based ion-
selective imaging. The sensor’s sensitivity and selectivity to potassium, as demonstrated by the 
studies on phantoms, using both traditional absorbance spectroscopy and PA measurements, are 
well suited for the biologically relevant extracellular K+ concentration range (1–100 mM). We also 
proposed, and demonstrated, a method of conjugating NIR dye molecules to the nanosensors, one 
that utilizes their surface modification by primary amine groups, thus, allowing having a 
fluorescence K+ sensor with a biologically relevant intracellular potassium concentration sensing 
range, from 20 mM to 1 M. Also, the NIR absorption can shift the working wavelengths of the 
nanosensors into the NIR range, thereby facilitating both a lower background noise and a better 
imaging depth, which would be crucial for in vivo imaging. These results provide a proof of 
concept for enabling a nanoparticle that serves as a PA ion-selective sensor, and also serves as a 
fluorescence based, ion-selective sensor. We also demonstrated the ease of attaching a tumor 
homing ligand to the NS, without affecting its functionality. This work is an important stepping 
stone and may have a large impact on future studies of the local potassium ion concentrations in 
the tumor microenvironment in vivo (extracellular through PA imaging and intracellular through 
fluorescence imaging), especially when considering the importance of investigating the local 
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hyperkalemia found in tumor microenvironments and its reported suppression of immunotherapy. 
Furthermore, this design for an ISPAO can be easily generalized to most biologically relevant ions, 
in analogy to traditional ISOs, as well as ISEs. 
  
77 
 
3.4 Methods 
Materials 
All of the chemicals were purchased from Sigma-Aldrich unless otherwise noted.  
 
K+ Nanosensor (K+ NS) preparation and characterization 
 
Figure 3.11 Synthetic route for Pluronic F68-Amine.39 
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Figure 3.12 Determining Primary amine group availability by using Fluorescamine assay. 
Excitation and emission spectra of PBS, Pluoronic F68, and amine modified Pluronic 
F68 (“Pluronic F68 Amine”) with fluorescamine addition. Into 1 mg/mL in PBS pH 
7.4, 50 μL of fluorescamine solution (3mg/mL in DMSO) was added and left at room 
temperature for 10 min. “PBS” indicates just fluorescamine and PBS pH 7.4. 
Amine modified Pluronic F68 was synthesized according to the previously reported methods 
(Figure 3.11).39 Pluronic F68 (75.6mg), Pluronic P123 (116 mg, BASF), amine modified Pluronic 
F68 (8.4 mg), Dioctyl Secabacate (14 μL), chromoionphore I (1.5 mg, 2.57 mmol), potassium 
ionophore III (5 mg, 5.15 mmol), sodium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (NaTFPB) 
(9.75mg, 11mmol), butyl methacrylate (5 μL), and 1,6-hexanediol dimethaacrylate (5 μL) were 
dissolved in ~ 10 mL dichloromethane. Then, the solvent was evaporated via rotary evaporation 
and left in the hood, open, overnight. The thin film generated at the round bottom flask was re-
suspended in Millipore water (10 mL). The suspended solution was flushed with Argon, while 
stirring, and 100 μL of ammonium persulfate (10% w/w in water) and 100 μL of N,N,N’,N’-
Tetramethylethylenediamine were injected into the solution to initiate radical polymerization of 
butyl methacrylate and 1,6-hexanediol diacrylate. After 2 hrs, the solution was purified by Amicon 
Ultra-15 Centrifugal Filter (100 kDa) with water (5 times) and Tris-HCl buffer (10mM) pH 7.4 (5 
~ 10 times) until the sensing solution turns blue. The size of K+ Nanosonophore was measured by 
79 
 
Dynamic Light Scattering (Beckman Coulter). Absorption spectra were obtained by a UV-VIS 
spectrometer (Shimadzu UV-1601) and fluorescence spectra were obtained by a fluorimeter 
(Horiba FluoroMax-3). The primary amine group availability on the K+ NS is confirmed by a 
fluorescamine assay (Figure 3.3 and Figure 3.12). Fluorescamine is a non-fluorescence molecule 
which fluoresces upon reacting with primary amines. An analogous batch of K+ NS was prepared 
with only Pluronic F68 instead of amine modified Pluronic F68. The fluorescence of fluorescamine 
in K+ NS was several folds higher than the fluorescence of fluorescamine in K+ NS without primary 
amine availability. 
Photoacoustic Spectroscopy Setup 
An optically clear polyvinyl chloride tube (I.D. x O.D. = 1/16 in. x 1/8 in.), containing solutions 
of the K+ NS (~5mg/mL), with various concentrations of K+ was placed in a water bath. An optical 
parametric oscillator (SLOPO Plus, Continuum), pumped with the second harmonic of a pulsed (5 
ns) neodymium-doped aluminum garnet (Nd: YAG) laser (Surelite, Continuum), was used for 
excitation (at 540 nm and 660 nm wavelengths, respectively). The PA signal was detected by a 
2.25 MHz unfocused ultrasonic transducer (V323, Panametrics) connected to an amplifier 
(5072PR, Olympus). The signal, digitalized by an oscilloscope (TDS540, Tektronix), was collected 
(averaged over 200 pulses). The laser pulse was focused with a converging lens where the sample 
is located inside the tube. The raw PA signals are normalized with the power of the laser and PA 
signals from the empty tube. The signal intensity at 540 nm when divided by the signal intensity 
at 660 nm gave the ratio used for calibration. With ratios determined for each sample at each 
potassium concentration (n = 4), an average and a standard deviation were obtained. 
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Photoacoustic Imaging Setup 
Gelatin phantoms were prepared by dissolving gelatin (from porcine skin) in hot water (80g/L) 
containing four 16 gauge needles. Then, the phantom cooled down to room temperature overnight. 
The 16 gauge needles were carefully removed and 4 different solutions of K+ NS (~5mg/mL) were 
carefully filled. As soon as the solutions were inserted, the PA images were acquired by an imaging 
system built on a commercially available research ultrasound platform (V1, Verasonics) with a 
linear array probe (CL15-7 with central frequency 11.25 MHz, Philips) working at 10 Hz. The 
laser pulse was diverged with a diverging lens so as to cover the entire imaging region (1.5 cm by 
3 cm). The phantom PA images (540 nm and 660 nm) were averaged over 50 images and were 
smoothed by a Gaussian filter. The phantom PA image at 540 nm was divided by the phantom PA 
image at 660 nm so as to acquire the ratiometric potassium image. 
Near Infrared absorbing K+ Nanosensor (NIR-K+ NS) preparation  
To a stirring 10 mL of solution (~15mg of the K+ NS in pH 7.4 phosphate buffered saline pH 
7.4), 0.05 mg of NIR-797 isothiocyanate (5mg/100 μL in DMSO) was added and stirred overnight. 
The solution was purified by an Amicon Ultra-15 Centrifugal Filter (100 kDa) with water (5 times) 
and Tris-HCl buffer (10mM) pH 7.4 (5 to 10 times). The prepared NIR-K+ NS was analyzed by a 
UV-VIS spectrometer and fluorimeter. 
F3-K+ NS preparation 
To modify the surface of the K+-NS, Bi-functional Polyethylene Glycol (MAL-PEG-SCM, 
2kDa, Creative PEGWorks) (8 mg) was added into K+-NS in PBS (pH 7.4) (50 mg/2.5mL). After 
30 min of stirring, it was washed with PBS using an Amicon Ultra-15 Centrifugal Filter (100 kDa) 
and an F3 Peptide (KDEPQRRSARLSAKPAPPKPEPKPKKAPAKKC, RS Synthesis) (22mg) 
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was added and stirred overnight. Cysteine (1.26 mg) was added and stirred for 2 hours to deactivate 
unreacted maleimide groups. The nanosensor solution was washed with water (5 times) then 
concentrated before usage. To confirm F3 conjugation onto the K+-NS, a separate batch was 
synthesized where the F3-peptide was pre-conjugated with NIR-797. The absorbance of NIR-797 
was still visible after the purification. 
Fluorescence Imaging Setup 
HeLa cells (ATCC) were cultured in DMEM medium supplemented with 10% Fetal Bovine 
Serum (FBS) and 1% Antibiotic-antimycotic. Cells were incubated with K+ NS (without amine), 
K+ NS, and F3-K+-NS (200 μg/mL) inside the growth medium for 30 minutes. After incubation, 
the nanosensor containing media were removed and washed with fresh colorless DMEM media (3 
times). Cell images were immediately taken on an Olympus IX71 microscope (10x) using a high 
resolution monochromatic camera (Retiga 6000, QImaging). Cells were illuminated using a broad 
excitation filter (510-550nm) with a red (630nm) emission filter; the filters were originally 
optimized, and used without any modification, for propidium iodide. Images were captured using 
the Micro-Manager software package - an extension of ImageJ. 
Degree of Protonation calculations 
We note that calibrations in this field are performed as protonation degree, termed π or (1-α), 
vs. concentration, for both absorbance and fluorescence based measurements. The PA calibrations 
were generated by simply using the ratios of the two signal intensities. This degree of protonation 
(π = 1-α) was calculated as described previously.3, 25 For the K+ NS, the degree of protonation, for 
a system using two sensing signals, follows the standards equation (1) below. 
π =  1 − α =
𝑅−𝑅𝑚𝑖𝑛
𝑅𝑚𝑎𝑥−𝑅𝑚𝑖𝑛
,                           (1) 
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where S is the scaling factor defined as A540nm at 0.01M NaOH/A540nm at 0.01M HCl, R is A660nm/A540nm, Rmin 
is A660nm at 0.01M NaOH/A540nm at 0.01M NaOH, and Rmax is A660nm at 0.01MHCl/A540nm at 0.01M HCl. 
For NIR-K+ NS, the degree of protonation, for a system using one sensing signal and one 
reference signal, follows the equation (2) below. 
π =  1 − α =
𝑅−𝑅𝑚𝑎𝑥
𝑅𝑚𝑎𝑥−𝑅𝑚𝑖𝑛
,                            (2) 
where R is A660nm/A800nm (or Fl660nm/Fl820nm), Rmax is using Rmax as A660nm at 10μM KCl/A800nm at 10μM KCl 
(or Fl660nm at 1M KCl/Fl820nm at 1M KCl), and Rmin as A660nm at 1M KCl/A800nm at 1M KCl (or Fl660nm at 10μM/Fl820nm 
at 10μM). Fl660nm represents all fluorescence intensities from Fl620nm to Fl700nm and Fl820nm represents 
all fluorescence intensities from Fl800nm to Fl840nm. 
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Chapter 4: Lifetime-based Photoacoustic O2 Imaging 
The introduction of this chapter has been adapted from a following submitted book chapter with 
minor modifications: 
Lee, C. H.; Jo, J.; Wang, X.; Kopelman, R. “Photoacoustic imaging of oxygen” (Chapter 10). In 
D. B. Papkovsky and R. I. Dmitriev (Eds.), Quenched-phosphorescence Detection of Molecular 
Oxygen. The Royal Society of Chemistry.(2018, In Press). 
 
4.1 Introduction 
Oxygen (O2) is inevitable for most living organisms. Humans, like other mammals, have 
evolved to precisely control the oxygen levels in their body. Imbalances or decreases in oxygen 
levels are expressed in various pathological states and can be fatal.1, 2 Especially in tumors, oxygen 
levels are known to be significantly lower than in normal tissue. This cancer phenomena of hypoxia, 
has been discussed and explained by the Warburg effect.3, 4 Hypoxia is observed not only in cancer 
but also in other inflammatory diseases, as well as in relation to the growth of stem cells.5, 6  
There are two main approaches of measuring oxygen levels through PA imaging. One approach 
is through direct ratiometric measurements of oxygen carrying proteins, such as hemoglobin and 
myoglobin.7-33 Hemoglobin (as well as myoglobin) changes its optical property, or simply color, 
with varying oxygen concentration, a well-established principle of pulse oximetry.34, 35 The ratio 
of the PA signals at two or more light wavelengths allows a non-invasive indirect oxygen 
measurement in vivo. Another approach of measuring oxygen levels through PA is an extension of 
time-resolved (or transient absorption) spectroscopy, called lifetime-based PA imaging.36-46 The 
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sensing mechanism is similar to that of phosphorescence quenching based oxygen sensors, but it 
is measured by PA imaging/spectroscopy, i.e. it is based on optical absorption rather than emission. 
Theories and examples for both methods are discussed in the subsequent sections. 
Blood oxygenation provides indirect measurements of oxygen through oxygen binding blood 
proteins, not by measuring tissue oxygen. It is important to note that tissue hypoxia is not always 
accompanied by ischemia.47 Moreover, intracellular oxygen monitoring can be as valuable a 
diagnostics tool as extracellular (i.e. blood) oxygen monitoring.48 So as to directly measure tissue 
oxygenation, photoacoustic lifetime measurements for oxygen sensing (PALT) was introduced.36, 
37, 40, 41, 43-46, 49-51 
 
Figure 4.1 Basic mechanism of PALT. (a) An oxygen sensing dye (a dye molecule with a 
long-lived phosphorescence) at its ground state (S0) absorbs the initial “pump” pulse 
(solid blue arrow). The excited molecule, through internal conversion (not shown) 
and intersystem crossing (ISC), quickly relaxes from the first excited singlet state (S1) 
to the first (lowest) triplet state (T1). Then, the “probe” pulse (solid green arrow) 
excites the dye molecules from the first triplet state to a higher lying triplet state. (b) 
The phosphorescence always decays exponentially and the exponential decay rate is 
known to correlate linearly with the oxygen concentration, typical of a first order 
reaction. The delay time between the pump and probe pulse (t = 𝛕) can be controlled 
by a delay generator. Multiple PA signals from probe pulses are collected by varying 
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the delay times so as to compute the exponential decay rate. 
The mechanism behind lifetime-based PA O2 sensing is equivalent to that of 
phosphorescence quenching based O2 sensing (Figure 4.1), but the signal is detected 
photoacoustically rather than optically. A standard phosphorescence based oxygen sensing dye 
can be excited into the first excited singlet state from its ground state by non-ionizing photonic 
radiation. This excited first singlet state can quickly relax into the lowest triplet state, which has 
a relatively long lifetime (typically in the μs range) due to the “forbidden” nature of the transition 
(requiring a change of spin, only allowed by a relativistic effect). Energy from the T1 state can 
also be transferred into the paramagnetic triplet ground state of a neighboring oxygen molecule, 
creating “singlet oxygen” and then other reactive oxygen species (ROS) as side products. Thus 
the phosphorescence is “quenched” (red arrow) by oxygen, and the lifetime of the 
phosphorescence is dependent upon the probability of colliding with O2 molecules, i.e. linear 
with the local O2 concentration. The dashed lines represent non-radiative relaxation, i.e. local 
heating that creates ultrasound, which can be detected by the PA signal, including the long-lived 
relaxation (green dashed arrow). 
The lifetime of the sensor dye’s excited triplet state can be shortened by its interactions with 
the local environment, such as molecular O2. The excited triplet state energy is thereby 
transferred into the paramagnetic “triplet”) ground state O2 molecule, creating singlet oxygen, 
and consequently other reactive oxygen species (ROS) as side products, while the sensor dye’s 
triplet state lifetime is shortened during the process. The lifetime of the excited state of the dye 
(as well as its phosphorescence) correlates linearly with the local O2 concentrations, as shown 
below by the Stern-Volmer relationship. 
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𝑇0
𝑇
= 1 + 𝑘𝑄𝑇
0𝑝O2.                            (1) 
where T is the lifetime, pO2 is the partial pressure of oxygen, T0 is the lifetime at pO2 = 0, and kQ 
is the quenching rate constant. 
 
Figure 4.2 Exemplary PALT setup. The “pump” and “probe” laser beams are guided into 
the target (sample) region, triggered by a delay generator. PA signals are collected by 
an ultrasound (US) transducer.  
Lifetime-based PA O2 monitoring employs two laser pulses, called “pump” and “probe” beams 
(Figure 4.2). The pump beam excites the oxygen sensing dye molecules into their first excited 
singlet state, which quickly transfers the energy into the first triplet state. The PA signal acquired 
from the “pump” excitation can be detected through an ultrasound transducer. The probe beam 
allows measuring the transient absorption of the dye’s triplet state, which can also be detected 
through the ultrasound transducer. By varying the delay times between the pump and probe beams 
(i.e. 1 μs, 2 μs, etc.), the exponential decay of the dye’s triplet state can be computed (Figure 4.1b). 
The decay rate and lifetime vary with the O2 concentration. It is also important to note that any 
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long-times transient absorption is not present for other biological chromophores, such as blood 
and melanin.  
It is important to note that PALT requires a oxygen sensing dye, which can be easily coupled 
with nanotechnology.52-56 Nanotechnology for biomedical applications has made significant 
advances over the past few decades. The main advantages relate to the delivery (i.e. by targeting) 
and protection (i.e., from blood enzymes).57, 58 The surface of the nanoparticles can be engineered 
to conjugate targeting moieties, such as peptides and antibodies. The nanoparticle (NP) matrix can 
physically encapsulate and protect the the sensing dyes so as to protect them from interactions with 
any larger biomolecules, such as proteins (including enzymes). Such interactions may cause 
degradation of dyes or alterations in their optical properties. The NP can also include additional 
calibration dyes required for reliable chemical analysis in vivo. Several chemical nanosensors have 
been developed for multiple analytes, including oxygen.58-63 
Here, a nanoparticle containing a known PALT oxygen indicator, Oxyphor G2, is prepared. 
The “proof-of-concept” experiment on the O2 sensing nanoparticle’s oxygen sensing capability 
was performed by generating a calibration curve with photoacoustically measured lifetime and 
known oxygen concentrations. Also, an initial experiment on a mouse model in vivo has been 
performed. The PA lifetime imaging is able to differentiate tissue oxygen levels. 
  
90 
 
4.2 Results 
Oxyphor G2 loaded polyacrylamide nanoparticle (G2-PAA NP) preparation and 
characterization 
 
Figure 4.3 Schematic of Oxyphor G2 conjugated polyacrylamide nanoparticles. 
 
Figure 4.4 Fluorescence spectra of G2 PAA NP (0.5 mg/ml) and Oxyphor G2 (5 μg/ml) 
in phosphate buffered saline (pH 7.4) with and without human serum albumin (HSA, 
4mg/ml). 
Figure 4.3 describes the synthetic schematic of Oxyphor G2 conjugated polyacrylamide 
nanoparticles (G2-PAA NP). The surface of the G2-loaded nanoparticles (G2-PAA NP) was 
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PEGylated so as to minimize immune system recognition and further modified with a targeting 
moiety, the tumor homing F3 peptide. The hydrodynamic size of the G2-PAA NP was ~80 nm 
when measured by dynamic light scattering. One of the greatest advantages of using nanoparticles 
is contents protection. Oxyphor G2 has been known to interact with HSA changing its optical 
properties.46 As shown in Figure 4.4, the fluorescence of free Oxyphor G2 has changed 
significantly when HSA (4mg/mL) was introduced into the solution. On the other hand, G2-PAA 
NP showed significantly less changes in fluorescence with HSA. Small molecules can interact with 
bigger bio-macromolecules such as HSA to undergo changes in its optical properties. The 
nanoparticle matrix can physically protect the sensing dye, Oxyphor G2, from interference, 
especially from large biomolecules, which would cause complications in in vivo studies. 
  
92 
 
PALT wavelength selection of G2-PAA NP 
 
Figure 4.5 PA signal from probe beam distribution with different wavelengths of pump 
and probe beams. The gray-scale represents PA signal intensities from probe beam 
excitation. 
Oxyphor G2, in its free dye form, has been tested with a PALT system previously.46 It is well-
known that absorption and fluorescence of the dye incorporated into nanoparticles are shifted 
from the dye’s innate optical properties.58  The PALT wavelengths used for Oxyphor G2 were 
630 nm for the pump beam and 950 nm for the probe beam. However, we observed that PA 
signal from 630 nm and 950 nm was not optimal for the G2-PAA NPs (Figure 4.5). PA signal 
intensities from different probe beam wavelengths (910 nm, 920 nm, 930 nm, 940 nm, and 950 
nm) with different pump beam wavelengths (620 nm, 630 nm, and 640 nm) were monitored. All 
15 combinations of pump and probe beam wavelengths were tested. As shown in Figure 4.5, the 
combination of 630 nm pump beam and 920 nm probe beam gave the highest PA signals. Thus, 
these two wavelengths hve been applied for later PALT experiments. 
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PALT calibration in vitro 
  
Figure 4.6 PALT with G2-PAA NP. The probe PA intensity was extracted with similar 
algorithm introduced in the previous section. 6 different pump-probe delays (5 μs, 10 
μs, 15 μs, 20 μs, 25 μs, and 30 μs) were taken for the exponential decay curve fitting: 
(a) when pO2 = 5%, (b) when pO2 = 12%, and (c) when pO2 = 21%. (d) Overlapped 
fitted exponential decay curves at different pO2. (e) Calibration curve with pO2 and 
computed exponential decay rates. 
The oxygen sensitivity of the G2-PAA NP was confirmed by the PALT experiment (Figure 
4.6). In Figures 4.6a, 4.6b, and 4.6c, the blue dots represent the extracted probe PA signal 
intensities, and the red lines represent the average exponential decay fit. As shown, the PA signal 
from the probe beam excitation decreased as the delay between pump and probe beam increases, 
indicating that the PA signal from the probe beam is relevant to the transient absorption. Also, the 
decay rate differs significantly at different oxygen concentrations (Figure 4.6d). The decay trend 
was fitted exponentially to give computed decay rates at different pO2. The G2-PAA NP’s 
computed exponential decay rates linearly correlate with pO2, as described by a Stern-Volmer 
relationship, 
𝑇0
𝑇
= 1 + 𝑘𝑄𝑇
0𝑝O2(Figure 4.6e). 
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PALT imaging of G2-PAA NP in vivo 
 
Figure 4.7 In vivo PALT imaging of G2-PAA NPs locally administrated in the thigh 
muscle of a mouse. Systemic oxygen saturation of the mouse was changed by 
adjusting the oxygen content in the inhaled gas. The colorimetric scale represents the 
normalized PALT exponential decay rates from 0 to 1 scale (AU). (a) Image when inhaling 
10% oxygen. (b) Image when inhaling 20% oxygen. (c) Image when inhaling 100% 
oxygen. PA imaging processing and analyses were performed by Dr. Janggun Jo. 
 
Figure 4.8 Normalized PALT exponential decay rate from the PALT images from Figure 
4.7 (10%, 20% and 100% oxygen were allowed to inhale). Error bars represent the 
standard deviation (n=3). 
An initial experiment on a mouse model in vivo has been performed (Figure 4.7). The 
oxygen saturation in the thigh muscle was imaged using PALT, where G2-PAA NPs were locally 
administrated into the thigh muscle. To change the tissue oxygen saturation level in the target 
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thigh muscle, we changed the content of oxygen in the breathing gas provided to the mouse. As 
shown, 100% oxygen inhalation (Figure 4.7c) exhibits much higher PALT decay rates in 
comparison to 10% (Figure 4.7a) and 20% (Figure 4.7b). As shown in Figure 4.8, average 
PALT decay rates from the PALT images show differences at different oxygen inhalation (Figure 
4.8). The decay rates presented by the PALT image can reflect the change in local oxygen 
saturation in the imaged thigh muscle. This is an important preliminary study suggesting that our 
G2-PAA NP is responsive to different oxygen concentrations in vivo. 
 
PALT imaging of G2-PAA NP in vivo tumor model 
 
Figure 4.9 NP accumulation PA image and PALT image of the tumor in vivo. The PA 
image in pseudo-color is superimposed on the gray-scale US image. US image is 
used to delineate the tumor boundary (red dashed line). (a) PA image of the tumor in 
vivo. The colorimetric scale indicates G2-PAA NP concentration in arbitrary units. 
(b) PALT image of the tumor in vivo. The colorimetric scale indicates PALT decay 
rate in arbitrary units. PA imaging processing and analyses were performed by Dr. 
Janggun Jo. 
The PA image shows nanoparticle accumulation around the tumor tissue in vivo (Figure 
4.9a). The PA signals from G2-PAA NP were extracted by using algorithms similar to those 
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described previously.58 The PA signal from NPs were spectrally unmixed using an algorithm 
similar to that introduced in PA hemoglobin oxygen monitoring (PA images from 576 nm, 584 
nm, and 630 nm are used). PA signals are treated so that deoxy-hemoglobin, oxy-hemoglobin, 
and the tumor-targeted G2-PAA NP are the only optical absorbers in the imaging region. It is 
clear from the image that more G2-PAA NP accumulated inside the tumor in comparison to 
outside of the tumor. 
PALT imaging of the tumor using the targeted nanosensor is also demonstrated in vivo 
(Figure 4.9b). The collected PA images were computed in a method similar to that described 
previously. The image contains raw PALT decay rates, normalized into a 0 to 1 scale. At a 
glance, the average PALT decay rate inside the tumor seems much less than the average PALT 
decay rate outside of the tumor. Also, the tumor boundary shows a slightly lower PALT delay 
rate (indicating a lower O2 concentrations), in comparison to the normal tissue outside of the 
tumor boundary.  
 
4.3 Discussion and Conclusion 
Oxyphor G2 embedded nanosensors have been applied for PALT spectroscopy and imaging. 
The PALT decay rates measured with G2-PAA NP showed a linear correlation with known oxygen 
concentrations in phantoms. In vivo PALT images, showing PALT decay rates in colorimetric scale, 
were taken with subcutaneous injection of G2-PAA NP into the thigh of normal mice. The mice 
were allowed to breathe with 10%, 20%, or 100% oxygen concentrations, and the PALT images 
showed clear differences in the computed decay rates for the three conditions. A PALT image of 
an in vivo tumor embedded mouse also showed spatial gradient dependent information from the 
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decay rates. 
Nanotechnology enabled PALT spectroscopy and in vivo PALT imaging have great potentials. 
The work is still inconclusive and needs more experiments. A key validation for this technique is 
to confirm that it is nanoparticle concentration independent. In case of in vivo studies, it is difficult 
to calculate exact nanoparticle concentrations. Other supplementary experiments, such as 
sensitivity of the G2-PAA NPs, minimal G2-PAA NP concentration requirements, photobleaching 
rate of the G2-PAA NPs, maximum imaging depth of the PALT imaging, minimum laser power 
requirement, etc., may all be in the future. 
We conclude that PALT can be much advanced by combination with nanotechnology. PALT 
indicating dyes can be encapsulated by nanoparticles, providing great potential advantages for in 
vivo studies. The nanoparticle matrix serves a critical role in chemical imaging in vivo, protecting 
the sensing dyes from direct interactions with large protein or enzyme molecules, as well as by its 
specific targeting ability. The nanoparticles can also be incorporated with other therapeutic agents 
(i.e., chemotherapy and/or photo-activated therapy), in addition to its sensing capability, thus 
turning into multifunction theranostic nanoparticles. 
  
98 
 
4.4 Methods 
Chemicals 
All chemicals were purchased from Sigma Aldrich or ThermoFisher Scientific unless otherwise 
noted. 
 
Synthesis of G2-PAA NP and F3 surface modification 
The Oxyphor G2 (4 mg) was conjugated with one of the monomers, 3-
(aminopropyl)methacrylamide hydrochloride salt (APMA, 53.6 mg), through carbodiimide 
crosslinking chemistry by stirring with 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 
2.9 mg or 6.5 mg) and Sulfo-N-hydroxysuccinimide (Sulfo-NHS, 8.22 mg or 18.5 mg) in 
Phosphate Buffered Saline (PBS, pH 7.4, 1.3 mL). Acrylamide (689.5 mg) was added into the 
mixture and stirred for 2 hrs in room temperature. Then, the crosslinker, 3-(Acryloyloxy)-2-
hydroxypropyl methacrylate (AHM, 321.3 mg) was added and vortexed to complete the 
monomer solution. The monomer solution was added and emulsified in a surfactant solution of 
AOT (1.6g) and Brij L4 (3.3 mL) in Hexane (45 mL). The polymerization was initiated by 
addition of N,N,N′,N′-tetramethylethylenediamine (TEMED) (100 μL) and 10% (w/w) 
Ammonium Persulfate (100 μL). The unreacted APMA provides primary amines used for later 
surface modification. The reaction was allowed to stir for 2 hours and hexane was removed by 
rotary evaporation. The prepared nanoparticles were washed with ethanol and water with Amicon 
Filter Cell using a 300 kDa filter, and then lyophilized. Although slight leaching of the dye was 
observed initially, during purification, there was no leaching during further steps of the synthesis. 
The surface of the SNARF-PAA NP was PEGylated and conjugated with tumor homing F3 
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peptides, following previous protocols64. The cancer targeting capability of our PAA NPs 
conjugated with F3 peptides has been extensively studied65-67. Bi-functional Polyethylene Glycol 
(MAL-PEG-SCM, 2kDa, Creative PEGWorks) (4 mg) was added into G2-PAA NP in PBS (pH 
7.4) (50 mg per 2.5mL). After 30 min of stirring, it was washed with PBS using Amicon Ultra 
Centrifugal Filter (100 kDa) and F3 Peptide 
(KDEPQRRSARLSAKPAPPKPEPKPKKAPAKKC, RS Synthesis) (11mg) was added and 
stirred overnight. Cysteine (0.63 mg) was added and stirred for 2 hours to deactivate unreacted 
maleimide groups. The NP solution was washed with water and lyophilized. The SNARF-PAA 
NP was characterized by UV-VIS spectroscopy (UV-1601 Spectrometer, Shimadzu), 
fluorescence spectroscopy (FluoroMax-3, Horiba), and Dynamic Light Scattering instrument 
(DLS, Delsa Nano C particle analyzer instrument, Beckman Coulter). 
 
In vitro PALT calibration setup 
G2-PAA NP (5mg/ml in PBS) solution was stored in a vial in continuous flow into an 
optically clear polyvinyl chloride tube (I.D. x O.D. = 1/16 in. x 1/8 in.) using a peristaltic pump 
sealed with rubber septum. A needle type oximeter (Microx TX3, Presens) was inserted directly 
into the NP solution and used to monitor oxygen concentrations for the calibration. The oxygen 
concentration was controlled by bubbling nitrogen or nitrogen/air mixture. It is important not to 
bubble during the measurements since bubbles might be introduced to the tube causing high 
noises. 
An optical parametric oscillator (Surelite OPO plus, Continuum) pumped with the second 
harmonic of a pulsed neodymium-doped aluminum garnet (Nd: YAG) laser generated the pump 
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beam at 630 nm. Another optical parametric oscillator laser (Vibrant B, Opotek) generated 
pulsed beam at 920 nm. The two laser beams were overlapped onto the tube while triggers of the 
two lasers were controlled by a delay generator (DG535, Standford Research Systems). PA 
signals were collected using cylindrically focused ultrasound transducer (V312, Panametrics). PA 
signals from probe beam excitations at different delay times between pump and probe beams (5 
μs, 10 μs, 15 μs, 20 μs, 25 μs, and 30 μs) were collected. The probe PA signal intensities were 
extracted by subtracting pump only excitation and probe only excitation from pump and probe 
excitation. The extracted PA signals were used to fit into exponential decay curve. 
 
PALT imaging setup 
The laser setup was similar to in vitro PALT setup. Laser light was allowed to cover the entire 
imaging region. PA imaging in vivo was performed using our US and PA dual imaging system 
built on a commercially available research US platform (V1, Verasonics, Redmond, WA) and a 
linear array probe working at a central frequency of 11.25 MHz (CL15-7, Philips, Andover, 
MA,). The details of this imaging system have been introduced in our former publication68. 
Powered by a GPU card, this dual-modality system can acquire PA and US images from the same 
sample at the same time, both in real-time fashion with a frame rate of 10 Hz (i.e. the laser pulse 
repetition rate). 
 
PALT imaging of G2-PAA NP in vivo 
All the procedures on live animals were approved by the University Committee on the Use 
and Care of Animals (UCUCA) of the University of Michigan (U-M). The mice were housed at 
101 
 
the U-M Medical School in the Unit for Laboratory Animal Medicine (ULAM). G2-PAA NP (20 
mg/ml in PBS, 0.1 mL) solution was injected into the thigh of mice. Mice were anesthetized with 
inhalation of 1.0 – 2.0% isoflurance mixing with oxygen or oxygen/nitrogen mixture making 
100%, 20%, or 10% oxygen concentration. After 20 min of inhalation of different mixtures of 
oxygen, PALT images were taken. The PA images from probe beam excitation were extracted by 
subtracting pump only excitation and probe only excitation from pump and probe excitation by 
pixels intensities. By computing exponential decay rates between PA images at different delay 
times, PALT images were prepared. 
 
PALT imaging of G2-PAA NP in vivo tumor 
All the procedures on live animals were approved by the University Committee on the Use 
and Care of Animals (UCUCA) of the University of Michigan (U-M). The mice were housed at 
the U-M Medical School in the Unit for Laboratory Animal Medicine (ULAM). Nude mice (5 
weeks old male, Athymic nude Fox/NU, Envigo) were used. 9L rat glioma cell line (American 
Type Culture Collection) was cultured in RPMI 1640 medium supplemented with 10% Fetal 
Bovine Serum (FBS) and 1% Antibiotic-antimycotic. Approximately 106 cells in 100 μL of 
culture media were subcutaneously injected on the back of each mouse. Each tumor was allowed 
to grow for 2-4 weeks until its volume reached around 0.5 cc as measured using a caliper. 
The nude mice were anesthetized with the inhalation of 1.0-2.0% isoflurane mixing with 
oxygen. The PALT images were acquired 60 min after the G2-PAA NP solution (20 mg/ml in 
PBS, 250 mg NP per kg body weight) tail-vein injection. PA images with 576 nm, 584 nm, 630 
nm were taken in order to provide the nanoparticle accumulation images by spectral unmixing 
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using a similar algorithm explained previously.58 PALT images were collected using similar 
method described previously. 
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Chapter 5: Summary and Future Directions 
 
5.1 Summary 
Nanoparticle research has been mostly focused on therapy rather than diagnostics. We believe 
that understanding the chemical information of tumors can guide a more accurate selection of 
treatments for each patient, and moreover, each tumor. Chemical information can guide us to our 
ultimate therapeutic goal, personalized medicine. Most common treatments for cancer include 
chemotherapy (affected by pH), radiation therapy (affected by O2), and immunotherapy (affected 
by K+). Here, some of the most recent advances regarding photoacoustic chemical imaging of each 
of the three analytes are introduced. 
In Chapter 2, the first demonstration of quantitative photoacoustic pH imaging is introduced, 
having been recently published in Nature Communications.1 Tumor acidosis, as a consequence of 
increased fermentative metabolism and poor perfusion, plays an important role in almost all steps 
of invasive growth and metastasis. Successful measurements of the extracellular pH of the tumor 
microenvironment can contribute to the clinical management of cancer as well as to basic research. 
We reported on an in vivo tumor pH mapping nanotechnology that includes the development of 
tumor-targeted, pH sensing nanoprobes, “nanosonophores”, and multi-wavelength photoacoustic 
imaging (PAI) integrated with ultrasound imaging. The optical pH indicator, SNARF-5F, i.e., 5-
(and-6)-Carboxylic Acid, was encapsulated into polyacrylamide nanoparticles with surface 
modification for tumor targeting. Protected by the polyacrylamide nanomatrix, the pH indicator’s 
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optical performance is not affected by proteins or enzymes, making possible the quantitative 
assessment of tumor pH in vivo. Facilitated by the multi-wavelength PAI plus spectral unmixing 
technique, the accuracy in measuring the pH is not susceptible to the background optical absorption 
of hemoglobin. As a result, both the pH levels and the hemodynamic properties in the entire tumor 
can be quantitatively evaluated, with high sensitivity and with high spatial resolution. The 
experiments on precisely-controlled phantoms validated the accuracy and robustness of this pH 
imaging technology, while experiments on a mouse cancer model demonstrated its good 
performance in vivo. The statistical analysis shows that the average pH levels quantified in the 
tumors were significantly lower than those in normal tissue, which was also confirmed by 
measurements via an invasive pH electrode used as a gold standard. 
In Chapter 3, the first photoacoustic and fluorescence optimized potassium sensor was 
described, which has recently been published in Analytical Chemistry.2, 3 Notably, ion selective 
optical nanosensors allow highly selective and accurate ion measurements in biological systems, 
without the physical limitations imposed by the use of ion selective electrodes. We reported the 
first example of a potassium selective nanosensor optimized for photoacoustic (PA) as well as 
fluorescence imaging. This potassium selective nanosensor (K+ NS) shows excellent response in 
the extracellular range, from 0 to 100 mM, as confirmed by both UV-Vis Spectroscopy and PA 
Spectroscopy, while also showing excellent response in the intracellular range, from 20 mM to 100 
mM, as confirmed by fluorescence spectroscopy. Furthermore, thi K+ PEBBLE showed a 2 orders 
of magnitude, or higher, selectivity to K+, relative to any other cations, such as Na+, Ca2+, and 
Mg2+. Notably, this example of a biological ion selective PA sensor can be easily applied to other 
biologically relevant ions, cations and anions (e.g., sodium, magnesium, calcium, chloride and 
nitrite), based on the standard principles of ion selective optodes, and thus to their utilization 
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for in vivo biological ion imaging. 
In Chapter 4, some of the initial studies of photoacoustic lifetime (PALT) O2 imaging were 
introduced. PALT imaging is based on transient absorption spectroscopy, using a phosphorescence 
quenching based oxygen sensor. The sensor can be incorporated into nanoparticles, thus granting 
targetability and protection of the sensing dye. A known PALT and phosphorescence quenching 
oxygen indicator, Oxyphor G2, is conjugated onto polyacrylamide nanoparticles (G2-PAA NP). 
The surface of the nanoparticle is further modified with the tumor homing F3-peptide. The oxyphor 
G2 is protected by the nanoparticle matrix, thus granting minimal interaction with human serum 
albumin, the most abundant protein in the body. The optical property of the dye, upon interaction 
with human serum albumin, would vary significantly. This innate oxygen sensing capability of 
G2-PAA NP was tested both in vitro and in vivo. 
 
5.2 Future directions for pH imaging 
For current diagnostics settings, the patients are first diagnosed through structural imaging 
(MRI, X-ray, PET, etc.). If doctors are suspicious of encountering a tumor in certain areas, the 
patient’s cancer is then confirmed through tissue biopsy. We envision that our quantitative pH 
imaging can replace the biopsy step. The NP can be injected to the patients and the quantified pH 
images can be provided within a day. The biomedical community already extensively studied pH 
in the normal body and found that the pH levels everywhere in the body are very strictly controlled. 
Also, if the NPs are accumulated into the suspected tumor’s tissue that would also provide a 
secondary proof that the suspicious tissue is in fact cancer. NPs can accumulate into tumors through 
both passive (EPR effect) and active targeting (F3 peptide in our studies, but can be replaced by 
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any other targeting moieties).  
Another direction we plan to study is the role of pH in relation to tumor metastasis. Essentially 
every tumor has different pH levels and this is often the tumor’s main characteristics. The more 
aggressive tumor may be smaller than the less aggressive tumor, but those aggressive tumors can 
be more acidic than other tumors. Because we can gather quantitative pH information, we can 
possibly, in the future, provide a statistical analysis on the relation between tumor pH and the 
tumor’s metastatic potential. Acidic pH can also influence the tumor’s resistance to chemotherapy, 
by up regulating the expression of p-glycoprotein, which increases drug efflux.4 There are other 
types of cancer drugs such as camptothecin, topotecan, and irinotecan, which are inactive at 
physiological pH and only become active at acidic pH. Gathering information on its pH can 
provide a precise selection of therapies that would be most effective for certain patients (also 
known as “precision medicine”). 
There are some of the technical limitations that need to be overcome. First, SNARF-5F is a 
dye that cannot be directly conjugated onto the nanoparticles. Thus, loading of the dye is limited. 
Higher loading can be highly beneficial potentially lowering injection dose. For imaging technique, 
the quantitative pH imaging can only be done up to 6 mm in depth due to the local fluence 
differences of different wavelengths. Another function, which estimates the fluence difference in 
muscle tissues, can be introduced to further increase the quantitative imaging depth limit. Another 
potential approach to enhance imaging depth is by replacing SNARF-5F with a different near 
infrared absorbing pH indicators. 
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5.3 Future directions for K+ imaging 
One of the most urgent directions for PA K+ imaging is to demonstrate it in vivo. To the best of 
our knowledge, there has not been an in vivo PA K+ imaging. However, there is a technical 
limitation imposed to the current sensor. The K+ NS is also sensitive to pH changes. Its calibration 
curve can be shifted slightly even with a 0.5 pH difference. The ion selective optodes essentially 
use pH indicators (chromoionophores) as the detection method; thus, influence of pH cannot be 
neglected in ion selective optodes, including the K+ NS. As introduced in this thesis, pH levels of 
the tumor are not consistent, which brings complication to quantification. Typical pH values in 
tumor models we have tested are higher than pH 6.6; thus, a new potassium sensor, which shows 
consistent calibration at pH values ranging from 6.6 to 7.4, should be prepared.   
Another interesting application would be in observing electrical cellular activity. Optical based 
chemical analysis methods provide a way to observe such cellular activity without the physical 
limitations imposed by electrodes. Most commonly used to monitor membrane potential are 
voltage-sensitive indicator dyes. However, the limitations preventing using voltage-sensitive dyes 
for in vivo studies are5: 
1. When administered intravenously, the dyes do not have specific binding, or so called 
“targeting” ability to target the specific cells. 
2. Most voltage-sensitive dyes exhibit significant toxicity. 
3. Most voltage-sensitive dyes use short wavelengths (<600 nm) of light, which limits deep 
tissue light penetration. 
Most voltage-sensitive dyes measure the electrochromic effect, also known as the Stark shift effect. 
111 
 
It is detected by a fluorescence emission change; however, fluorescence imaging has limited use 
in vivo due to the light penetration depth limit, even with longer wavelength light, because of the 
need to detect the light (emission) that emanates back from the response area. It is possible to 
overcome the light penetration depth limit of the conventional fluorescence imaging modality by 
applying photoacoustic (PA) Imaging.6  
As an alternative to using voltage-sensitive dyes, ion concentration gradients can be measured 
in order to gather cellular activity information. Membrane potentials, or “action potentials”, are 
generated by voltage-gated ion channels as the nerve cells or muscle cells maintain the homeostasis 
of ion concentration within the cells.7 Overcoming the physical limitations and invasiveness of ion 
selective electrodes, ion selective nanoparticles (nanosensors) can be delivered non-invasively and 
enable real-time monitoring.8-10 Ion-selective nanoparticles are essentially similar to ion-selective 
electrodes, where the membrane of the electrode is supplanted by the surface medium of the 
nanoparticle. Molecular sensors can be incorporated into their polymer matrix medium which 
serves to protect the molecular sensors from degradation and enables targeting a cancer or other 
specific tissue by conjugating a cell-targeting moiety onto the surface of the matrix.2, 11 
 
5.4 Future directions for O2 imaging 
Although some of the initial studies have been shown in this thesis, there are still more 
experiments left to be done in order to conclude the story. The in vivo experiments presented need 
to be repeated (currently, n=2) to validate our findings and acquire statistical significance, along 
with some supporting in vitro and ex vivo experiments. For example, it is important to confirm that 
the technique is nanoparticle concentration independent, since the nanoparticles are spread 
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unevenly throughout the imaging region. 
A side product of PALT is the production of reactive oxygen species (ROS, including singlet 
oxygen, superoxide, H2O2, etc.). This mechanism is actually also shared with photodynamic 
therapy (PDT). PDT is a therapeutic modality, which was originally developed for cancer treatment 
and later extended to different diseases such as bacterial and viral infections as well as cardiac 
arrhythmia.12-19 Photosensitizers receive light energy, which is transferred into nearby O2 
molecules, so as to produce ROS. The excess ROS causes oxidative stress within the cell, leading 
to cell death. PDT is a highly selective therapeutic modality which requires spatial and temporal 
concomitance of all 3 components (light, photosensitizer, and O2). During PDT, the molecular O2 
is essentially consumed. PALT has thus the potential to be combined with PDT so as to enable real-
time therapeutic monitoring, thereby acquiring a theranostic operation, for therapy guidance, 
towards the ultimate therapeutic goal of personalized medicine (Fig 10).20-22 An initial study of 
this application is introduced in the Appendix section. 
PALT can also be applied to different analytes, such as glucose. We have previously used 
optical oxygen sensing nanoparticles for intracellular glucose measurements.23 The nanosensor 
was composed of a polyacrylamide based nanoparticle containing an oxygen sensitive 
fluorescence indicator (Ru[dpp(SO3Na)2I3)Cl2), an oxygen insensitive reference fluorescence dye, 
and glucose oxidase. Glucose oxidase catalyzes oxidation of glucose to produce D-gluconolactone, 
which hydrolyzes into D-gluconic acid. The oxidation results in a local depletion of oxygen, which 
can be detected by the oxygen indicator. 
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Appendix A 
Monitoring photodynamic therapy (PDT) using photoacoustic lifetime based oxygen 
sensing 
 
This section has been adapted from a following conference paper with modifications and updates: 
Jo, J.1; Lee, C. H.1; Kopelman, R.; Wang, X., “Lifetime-resolved photoacoustic (LPA) 
Spectroscopy for Monitoring Oxygen Change and Photodynamic Therapy (PDT)”, Proc. SPIE, 
9708, Photons Plus UltrasoundL Imaging and Sensing, 97081L, 2016. 1Indicates co-first 
authorship 
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Figure A.0 Graphical abstract 
 
A.1 Introduction 
Photodynamic therapy (PDT) is a promising therapeutic modality for various tumors1-5. It is a 
highly targeted/local treatment, as the illumination is localized to the target tissue, with a certain 
wavelength of light used to excite a photosensitizer (PS) so as to convert the local ground state 
oxygen (3O2) molecules into cytotoxic reactive oxygen species (ROS). The ROS cause oxidative 
stress within the cells, inducing cell death by apoptosis, necrosis or a combination thereof 1-5. 
Upon light excitation, the PS molecule’s excited singlet state, through internal conversion and 
intersystem crossing, quickly relaxes to the excited triplet state of the PS. The emission from this 
triplet state (phosphorescence) is typically slow, due to its being a quantum mechanically 
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forbidden process, requiring a change in electronic spin state 1-5. As a result, the excited PS state 
lifetime is long enough to allow quenching by collisional interaction with nearby 3O2 molecules, 
thus creating 1O2 and other ROS. PDT’s advantages over conventional therapies are: (1) having 
minimal long-term toxicity effects, (2) enabling highly selective localized treatments by the 
focused laser beam, (3) enabling repeated treatments at the same site, and (4) presenting a 
significantly lower risk of side effects, compared to surgery, chemotherapy or ionizing radiation 
treatments. In addition, PDT can be employed to virtually any type of cancer. Numerous 
worldwide clinical trials have shown PDT as an effective and safe modality for various cancers 1-
3. Due to the increased attention to PDT, researchers have been interested in optimizing 
nanophotosensitizers, which have the potential to increase efficiency, targetability (with double 
targeting enabled by the focused laser beam and by the nanoparticle navigation of the PSs), and 
biocompatibility 4, 5. Having developed nanophotodynamics, i.e. nano-enabled PDT 6-11, as well 
as Photoacoustic oxygen sensing via the method of PhotoAcoustic LifeTime (PALT) 
measurement 12-15, we here combine the two methods for achieving the added potential of 
personalized theranostic (therapeutic plus diagnostic) operation, i.e. precision medicine. 
Methylene Blue (MB) is a promising candidate for working as a dual PS-oxygen-
activator/sensor, due to its high triplet quantum yield (~0.5), enabling efficient energy transfer to 
oxygen and thus leading to high efficacy PDT. Moreover, MB has Near Infrared absorption 
wavelength (λmax = 664 nm in aqueous media), allowing deeper tissue penetration 16. The 
feasibility of MB oxygen sensing has already been explored previously 13, 14.  However, MB in 
free molecule form has only limited use in vivo, because the MB molecules, without being 
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protected, get reduced into PDT inactive, colorless isomeric molecules (leuko-MB) by blood 
enzymes 6, 8, 16. Also, at higher concentrations, MB molecules may form aggregates that reduce 
their luminescence quantum yield, due to “self-quenching”, leading to a decrease in PDT efficiency 
8, 9, 16. Furthermore, MB molecules cannot specifically target tumors when intravenously injected. 
In some of our previous works, MB loaded polyacrylamide nanoparticles (MB-PAA NP) have been 
developed, using several different methods to maximize their PDT efficacy 6-10. Notably, the PAA 
matrix protects the MB molecules from the blood enzymes, thus avoiding isomerization of MB 
into leuko-MB. According to our previous measurements, in the presence of reducing enzymes, 
over 80% of the free floating MB molecules’ fluorescence disappears after 1 hr; however, only less 
than 10% of the MB-PAA NP fluorescence disappears under the same condition 6. Also, the amine 
functionalized PAA NPs enable surface functionalization, for attachment of tumor targeting 
moieties, such as the F3 tumor homing peptide, via conjugation with bi-functional polyethylene 
glycol, thus navigating the MB PS specifically to and into the tumor cells 7, 10, 17-19.  
Oxygen depletion during PDT has been studied previously, and its relevance for PDT efficacy 
and its effects on tumor survival have been monitored very closely 20-22. However, most 
experiments were performed using secondary probes, such as hypoxia markers 21. The others 
involved the sticking-in of invasive oxygen sensing electrodes 23. Presently, there is still not a good 
way for non-invasive monitoring of oxygen depletion during PDT, and in real-time fashion. PA 
imaging is a non-invasive imaging technique, using only non-ionizing light and external ultrasound 
detectors. One of the greatest advantages of PA imaging, for both structural and chemical imaging, 
compared to conventional fluorescence, is the deeper tissue penetration capability, meaning better 
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feasibility for in vivo studies. The PALT system uses two laser beams: a “pump” beam and a “probe” 
beam. Upon the photon pump-beam excitation, an oxygen indicator dye molecule’s excited singlet 
state undergoes internal conversion and intersystem crossing, quickly relaxing to the excited triplet 
state. The PA signal induced by the probe beam measures the molecule’s transient absorption (T1 
to Tn) of the excited triplet state. By changing the time delay between the pump and probe beams, 
exponential decay curves of the PA amplitudes are derived from the probe beam. This exponential 
decay rate of the PS in the excited state correlates directly with the oxygen concentration in the 
medium, as the oxygen quenching is a pseudo-first-order chemical reaction.  
Hereby we demonstrate a personalized theranostics method, aimed at precision cancer 
medicine, by combining PDT and PALT oxygen sensing. The MB-PAA NP itself has a unique 
capability of enabling both nano-PDT and 3O2 monitoring. It may not only perform separately PDT 
and 3O2 monitoring, but can also be used to study the PDT efficacy, by simultaneous in situ 3O2 
depletion monitoring, through PALT measurement. This new method should allow one to 
determine, in a non-invasive manner, in vivo, the correct drug/light dosage (i.e. therapeutic window) 
for different types of cancers and for individual patients, as needed for precision medicine. 
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A.2 Results and discussion 
Characterization of MB loaded polyacrylamide nanoparticles (MB-PAA NPs) 
 
Figure A.1 (a) DLS of MB-PAA NPs (b) UV-Vis absorption spectra of MB-PAA NPs in 
PBS pH 7.4 buffer. 
MB-PAA NPs were synthesized as previously described 6. Dynamic Light Scattering 
measurements were taken to determine the hydrodynamic size of the MB-PAA NPs. The average 
size distribution was 73.7 nm (±6.8 nm) (Figure A.1a). The hydrodynamic size of the MB-PAA 
NPs is also optimal for passive targeting of cancer (10 nm to 100 nm) 4, 24. The MB-PAA NPs 
exhibit absorption maxima at 669 nm and 619 nm, as previously reported 6. The peak at 669 nm 
corresponds to the MB monomer peak while the peak at 619 nm corresponds to the aggregated 
MB dimer peak.6, 16 The dimer and monomer absorption ratio stays constant at different 
concentrations of the MB-PAA NPs; thus, the solvent does not play a critical role in the aggregation 
of the MB embedded inside the MB-PAA NPs, as shown in Figure A.1b.  
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Figure A.2 The k value determination of ROS production by MB-PAA NPs with different 
excitation wavelengths. [ADPA]i indicates the initial ADPA fluorescence and 
[ADPA]f indicates the ADPA fluorescence after quenching by ROS. 
The ROS production (photo-cytotoxicty) of the MB-PAA NPs was measured by using the ROS 
quenchers, ADPA, and their fluorescence decay kinetics.6, 9, 25 As pointed out, the ADPA 
fluorescence decays follow first order kinetics under ROS exposure, and the k value indicates the 
decay constant. When the 669 nm wavelength light was used to excite the MB-PAA NPs, the k 
value was found to be 0.00131 s-1, which is comparable to the previously reported k value, 0.00134 
s-1.6 On the other hand, a 619 nm excitation of the same sample produced only ~30% of the ROS 
produced by the 669 nm excitation (Figure A.2). As discussed in previous section, MB-PAA NP 
exhibits two absorption peaks, which are a monomer peak at 669 nm and a dimer peak at 619 nm. 
One of the most dominant pathways for PDT needs the excited photosensitizers to be relaxed into 
the first triplet state. The dimer peak excitation loses most of the excited energy through “self-
quenching” releasing its energy mostly through heat to cause less efficient PDT. The 650 nm 
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excitation, which was used for both PDT and PALT experiments, showed only a small reduction 
in ROS production rate, compared to the 669 nm excitation. The 650 nm position was chosen so 
as to compensate between the ROS production during PALT measurements of oxygen 
concentration and retaining the PDT effect causing the oxygen depletion. 
 
PDT under the microscope using 9L glioma cells 
 
Figure A.3 Fluorescence microscope images of Live (Calcein AM, green)/Dead (PI, red) 
cell assays, before and after PDT treatment. The blue box (top half) designates the 
illumination area. 
In Figure A.3 the blue box, at the top, indicates the area of illumination. PDT was performed 
without rinsing off the MB-PAA NP solution in the cell media. This was to give a better comparison 
with the later described pulsed laser PDT experiments and PALT experiments, where we used the 
MB-PAA NP solution without rinsing. Only the region indicated in the blue box was illuminated 
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with the red laser. After 30 min of illumination, all of the cells had strong PI (red) uptakes and 
reduced Calcein AM (green) signals, thus indicating cell death. As shown in Figure A.3, only the 
area that was illuminated (blue box) showed PI uptake (red) while the other half did not.  
For the confocal microscopy experiment, the top half of the cells showed PI uptake while the 
bottom half did not, indicating strongly that the PDT was only operative in the area of illumination. 
Because the MB-PAA NP solution was used without a rinsing off of the nanoparticle solution that 
did not enter the cells, the ROS are expected to be produced both inside and outside of the cells. 
However, the results suggest that the ROS produced inside the illumination area do not travel far 
enough to affect nearby cells, which is expected from the short lifetimes, and thus short diffusion 
lengths, of most ROS species.26, 27 Notably, the nanoparticle uptake was also confirmed by 
microscopy. (Figure A.3)  
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PDT with pulsed laser and oxygen depletion during PDT 
 
Figure A.4 Blue Boxes indicate the cell survival rate during PDT, using pulsed laser, and 
Red squares indicate the oxygen concentration at each time point during PDT. All 
oxygen concentrations were measured by the oximeter. “Oxygen Concentration 
without PDT (%)” refers to no light illumination with identical conditions to 
“Oxygen Concentration during PDT (%)”. 
PDT using pulsed lasers has been reported previously.28, 29 PDT was performed using a pulsed 
laser system and the cell viability was monitored (Figure A.4). The oxygen concentration was 
plotted together with the cell survival rate, during PDT, as determined through flow cytometry. 
After 20 minutes of illumination with the pulsed laser, almost the whole population of cells 
underwent cell death. Also, the oxygen concentration was monitored, with and without PDT. The 
oxygen concentration dropped much more drastically with continuous “pump” beam exposure (red 
line) compared to without light exposure (purple line). The slight oxygen concentration decrease 
0
5
10
15
20
25
0
20
40
60
80
100
120
0 min 5 min 10 min 20 min
O
xy
ge
n
 C
o
n
ce
n
tr
at
io
n
 (%
)
R
e
la
ti
ve
 C
e
ll 
V
ia
b
ili
ty
 d
u
ri
n
g 
P
D
T
 (
%
)
Time of illumination (min)
Relative Cell Viability(%)
Oxygen Concentration
during PDT(%)
Oxygen Concentration
without PDT(%)
125 
 
without light exposure case (purple line) is attributed to the cell metabolism. We did not observe 
any oxygen depletion when cells were not present in the solution (just MB-PAA NP solution with 
light illumination). We believe that most of the oxygen depletion shown in Figure A.4 (red line) 
is caused by PDT, with only a small fraction thereof due to cell metabolism (purple line), which 
can be corrected for. The oxygen is consumed during the first stage of PDT, producing ROS as a 
side product. Presumably, the ROS then oxidize nearby unsaturated biomolecules, disrupting the 
cell membranes, organelles, and proteins, thus leading to cell death. Thus, the oxygen depletion 
during PDT may infer cell death and can be used to monitor its therapeutic efficacy.  
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Oxygen depletion measured with PALT 
 
Figure A.5 The Green Triangles indicate the PALT decay rate measurements, after 
illumination (0 min to 30 min), and the Red Squares indicate the oxygen 
concentrations measured using the oximeter as the gold standard. 
The PALT measurement was applied to monitor the oxygen concentration during PDT. An 
overlay of oxygen concentration decays, measured by oximeter and PALT is depicted in Figure 
A.5. The 650 nm laser was continuously illuminating during the 20 min period while the 810 nm 
laser was only illuminating during the PALT measurements (less than 1 min). The PA signals from 
the 810 nm laser (the “probe” beam) were exponentially fitted with delay times (1, 2, and 4 μs) 
signals, to give the exponential decay rate constants for the MB-PAA NPs at different oxygen 
concentrations. The oxygen concentration (red squares, Figure A.5) was measured by the oximeter. 
The oxygen consumption rate falls off significantly after 20 min of illumination (Figure A.5, 
red line). We suspect that this is due to almost complete cell death by that time, so that the ROS 
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produced from PDT, not finding nearby oxidation sites, convert back to triplet (ground state) 
oxygen. Literature reports state that singlet oxygen, which is believed to be the majority of ROS, 
does not diffuse far 26, 27. Also, we have performed an analogue experiment under the confocal 
microscope (Figure A.3). The results suggest that the ROS produced inside the illumination area 
do not travel far enough to affect un-illuminated nearby cells, which is expected from their short 
lifetimes, and thus short diffusion lengths 26, 27.  
 
A.3 Conclusion 
We have demonstrated the feasibility of using the MB-PAA NPs as an oxygen sensor. 
Previously, we demonstrated PALT both in vitro and in vivo using other oxygen sensors 12, 15. We 
employed a double laser system, with “pump” and “probe” beams, for PALT on MB-PAA NPs. 
While the PDT experiments were conducted under the same conditions as previously, this time the 
PALT method was used to measure the oxygen concentration. As depicted in Figure A.5, the 
exponential decay rate shows a strong correlation with the oxygen concentration of the solution as 
measured with a standard oximeter. The oxygen concentration is constantly decaying because of 
the PDT process. Thus, we thought that the measurement time was a critical factor in minimizing 
the PDT effect during measurements. Because we wanted to demonstrate the feasibility of 
measuring oxygen in situ, we minimized the “pump” beam exposure during “probe” beam 
measurements, taking just 4 spectra (3 spectra from delay time signal and only 1 “pump” beam 
signal as background) in total. A larger number of delay times, from 0.1 μs to 20 μs, should 
decrease the errors in the exponential fit.  
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We believe that this is the first report to demonstrate the feasibility of MB-PAA NPs to be 
applied as both a diagnostic (measuring oxygen) and a therapeutic (PDT) modality. This unique 
dual capability of the MB-PAA NPs allows us to demonstrate here a potential non-invasive 
theranostic operation, by monitoring oxygen depletion during PDT in situ, without the addition of 
secondary probes. Specifically, we demonstrated the correlation between the oxygen concentration 
and the cytotoxicity of PDT, for 9L glioma cells, showing that the oxygen depletion during PDT 
can be monitored using PALT. The same approach can be further applied to in vivo studies, when 
treating tumors with PDT and simultaneously monitoring/imaging tissue oxygen photo-
acoustically. Another potential advantage of the MB-PAA NPs is that their 619 nm light excitation 
may be applicable for enhancing PA structural imaging. As pointed out above, although the 
absorbances at 619 nm and 669 nm were found to be similar, the PDT efficacy at 619 nm was ~70% 
less than that with the 669 nm excitation (Figure A.2). Therefore, such use of MB excitation at 
619 nm would allow longer-term PA structural imaging without much photo-damage to the cells. 
Also, similar to the use of Coomassie blue PAA NPs 17, 18, we presume that the MB-PAA NPs could 
also be applied for tumor surgery delineation, by offering an optical contrast that is visible to the 
surgeon’s naked eye.  
 
A.4 Methods 
Materials 
Acrylamide (AA), poly(ethylene glycol) dimethacrylate, Mn 550, (PEGDMA), ammonium 
persulfate (APS), N,N,N′,N′-tetramethylethylenediamine (TEMED), sodium 
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dioctylsulfosuccinate (AOT), Brij 30, dimethyl sulfoxide (DMSO), Ethanol, phosphate buffered 
saline (BioReagent, pH 7.4, for molecular biology) and hexane were purchased from Sigma-
Aldrich (St. Louis, MO, USA). N-(3-aminopropyl)-methacrylamide hydrochloride (APMA) was 
purchased from Polysciences (Warrington, PA, USA). Dicarboxymethylene blue NHS ester 
(DCMB-SE) was purchased from European Molecular Precision Biotech (Berlin, Germany). 
Anthracene-9, 10-dipropionic acid disodium salt (ADPA), RPMI 1640 Medium, 100X Antibiotic-
Antimycotic, Heat Inactivated Fetal Bovine Serum (FBS), Calcein AM, and Propidium Iodide (PI) 
from Life Technologies (Carlsbad, CA, USA). Annexin V:FITC Apoptosis Detection Kit I was 
purchased from BD Biosciences (San Jose, CA, USA). 9L rat gliosarcoma cell line was obtained 
from American Type Culture Collection (Manassas, VA, USA). The water was purified with a 
Milli-Q system from Millipore Corporation (Billerica, MA, USA). All chemicals were used 
without further purification. 
 
Preparation of MB-PAA NPs 
The MB-PAA NPs were prepared by MB conjugation to PAA as in a previously reported 
method.6 All reactions were performed in the dark. The monomer solution was prepared as follows. 
DCMB-SE (5mg dissolved in 100 μL of DMSO) was added into 0.93 mL of Phosphate Buffered 
Saline (PBS, pH 7.4) containing AA (368 mg) and APMA (28mg). The monomer solution was 
stirred for 2 hr at room temperature. Then, AOT (1.07g) and Brij 30 (2.2 mL) were added into 30 
mL of Hexane in a round bottom flask equipped with a stirring bar. After 30 min of argon flushing, 
the monomer solution was injected and flushed with argon for another 15 min. The radical 
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polymerization was initiated by addition of 100 μL of TEMED and 100 μL of APS (15mg / 100 
μL in water), while stirring. After 2 hr, the hexane was evaporated with a rotary evaporator and the 
resulting MB-PAA NPs were suspended in Ethanol and transferred into an Amicon Stirred 
Ultrafiltration Cell equipped with a Biomax 300 kDa membrane. The solution was washed with 
Ethanol and water several times so as to remove any unreacted monomers and surfactants. Then, 
the MB-PAA NPs water suspension was freeze-dried and stored at -20oC. 
 
Characterization of MB-PAA NPs 
A Dynamic Light Scattering instrument (DLS, Delsa Nano C particle analyzer instrument, 
Beckman Coulter, Brea, CA, USA) was used to determine the particle size. A UV-1601 
Spectrometer (Shimadzu, Kyoto, Japan) was used for the Absorption spectra and a FluoroMax-2 
Spectrofluorometer (Jobin Yvon Horiba, Kyoto, Japan) was used for the Fluorescence spectra. 
Both spectrometers were used to determine the dye loadings and NP’s characteristics, comparing 
to the previously reported MB-PAA NP 6. 
The ROS production rate can be quantified by the “k value”, using the ADPA method.6, 9, 25 
ADPA is an ROS scavenger which irreversibly binds with ROS under room temperature. The ROS-
oxidized ADPA product has no fluorescence. The reaction between the ROS and the ADPA follows 
pseudo first order kinetics, and the decay rate of the ADPA emission is the k-value. To 2 mL of 
MB-PAA NP (1mg/mL in PBS), 80 μL of ADPA (100 μM in water) was added. The emission 
spectra of ADPA (370 nm excitation) were taken, while illuminating with a given wavelength of 
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light (619 nm, 650 nm, or 669 nm), over different time periods (0 sec, 60 sec, 120 sec, and 420 
sec). The k value was calculated as in our previously reported method.6, 9, 25 Notably, while both 
619 and 669 nm excitation have similar absorbance coefficients for these MB-PAA NPs, the 
former’s ROS production efficiency is about 70% lower.  
 
PDT using Pulsed Laser / Cell viability Experiments 
The 9L cells (106 cells/ml) were incubated with a MB-PAA NP solution, containing a 1mg/ml 
FITC Annexin Binding Buffer, for 2 hr. Then, the cell containing solution was transferred into 
clean plastic cuvettes and sealed with a rubber septum to minimize air flow into the cuvette. An 
optical parametric oscillator (Surelite OPO plus, Continuum) pumped with the second harmonic 
of a pulsed neodymium-doped aluminum garnet (Nd: YAG) laser was used, with a pulse-width of 
5 ns, at 650 nm wavelength (10mJ), for different time periods (0 min, 5 min, 10 min, and 20 min). 
The light source was scattered so as to cover the entire area of the cuvette. Each sample was then 
transferred into a round bottom tube and then FITC-Annexin V (5μL/105 cells) and PI (5μL/105 
cells) were added into the test tubes. The tubes were incubated for 10 min, at room temperature, 
before introduced to a Flow Cytometer (MoFlo Astrios, Beckman Coulter). 
 
Oxygen Depletion during PDT 
The oxygen concentration was measured by an oximeter (Microx TX3, Presens), every 5 min. 
The 9L cells (106 cells/ml) were incubated with MB-PAA NPs for 2 hr and the oxygen 
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concentration was monitored with and without 650 nm laser illumination (i.e., with or without 
PDT). 
 
PALT Spectroscopy setup 
The schematic of the experiment setup for PALT is shown in Figure A.6. An optical parametric 
oscillator (Surelite OPO plus, Continuum), pumped with the second harmonic of a pulsed 
neodymium-doped aluminum garnet (Nd: YAG) laser, was used as the “pump laser”, with a pulse 
width of 5 ns and a pulse energy of 10 mJ, at 650 nm wavelength. For the “probe laser”, another 
optical parametric oscillator laser (Vibrant B, Opotek) generated pulsed beam, with a 7-mJ pulse 
energy, at 810 nm of wavelength was used. The triggers of the two lasers were controlled by a 
delay generator (DG535, Stanford Research Systems). The two laser beams were overlapped on 
the transparent cuvette containing the 9L cells pre-incubated with the MB-PAA NPs. The 
incubation method and conditions were identical to those in the Flow Cytometry experiments (2 
hr). The Photoacoustic (PA) signal was detected by a hydrophone (HNC-1500, ONDA) and 
amplified with a preamplifier (AH-2010-CDBNS, ONDA) and an amplifier (5072PR, Olympus). 
The signal, digitalized by an oscilloscope (TDS540, Tektronix), was collected (averaged over 50 
pulses).  
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Figure A.6 The schematic of the experimental PALT setup, also used for PDT  
To summarize, in our PALT experiments, the MB-PAA NPs are first excited with a pump beam 
at 650 nm, followed by a probe beam at 810 nm. The probe beam response measures the MB’s 
transient absorption in the excited triplet state. By varying the time delay between pump and probe 
beams, the exponential decay curves of the photoacoustic amplitudes can be obtained, by 
measuring the signal from the probe beam 12-15. The rate of the exponential decay correlates 
directly with the oxygen concentration in the medium.  
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